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Second International Symposium on
Prevention of Breast Cancer
Growth control of the normal breast
R.C. Coombes
St George's Hospital, Blackshaw Road, Tooting, London
SWJ7 OQT, UK.
We have studied the normal breast using immunocyto-
chemistry and cDNA probes for steroid hormone receptors
and growth factors and their receptors. We find that
progesterone, oestrogen and vitamin D receptor are present
in normal breast cells and that the oestrogen receptor is
down-regulated in the luteal phase of the menstrual cycle. In
contrast progesterone receptor does not appear to change.
Concerning growth factors, all normal or benign breast
samples studied have been found to contain epidermal
growth factor receptor messenger RNA (mRNA). We also
find significant amounts of transforming growth factor,
alpha and beta mRNA and we are currently investigating the
control of expression of these growth factors.
Significant differences have been found in cancer tissue.
Transforming growth factor beta is present in higher
amounts than in normal tissue and epidermal growth factor
mRNA is absent in some breast cancer samples, particularly
oestrogen receptor positive breast cancers.
Further studies are being carried out to determine the
cellular localisation of these factors and the way that they
control normal and malignant cell growth.
Exogenous hormones and breast cancer
M. Vessey
Department of Community Medicine and General Practice,
Radcliffe Infirmary, Oxford OX2 6HE, UK.
Oestrogens have been given to women on a large scale in
three particular circumstances: (a) during pregnancy to try.to
prevent miscarriage and late pregnancy toxaemia; (b) around
the time of the meopause to try to relieve the menopausal
syndrome and to prevent the development of osteoporosis;
and (c) during the childbearing years (in combination with
progestogens) to prevent pregnancy.
The epidemiological studies which have investigated the
effects of exogenous oestrogens on the breast will be
reviewed briefly. There is suggestive, but not conclusive,
evidence that each of the three types of exposure listed above
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may be associated with a small increase in the risk of breast
cancer.
Chemoprevention of contralateral breast cancer with
hydroxyphenyl-retinamide (Fenretinide)
U. Veronesi
Instituto Nazionale per lo studio e la cura dei Tumori, Via
G. Venezian 1, 20133 Milan, Italy.
Fenretinide (HPR) is a synthetic retinoid which has been
shown to have a chemopreventive effect on carcinogen-
induced epithelial tumours in experimental animals. HPR
has been proposed, because of its efficacy and low toxicity in
animals, for chemopreventative evaluation in humans. Thus,
a randomised phase 1 trial was conducted to select a dose
which can be administered over a long period of time with
acceptable toxicity. The number of breast cancer patients
randomised was 101 and during the first 6 months of the
study the patients were divided into four groups (placebo,
100mg, 200mg or 300mg per day HPR). During the
following 6 months they all received 200mg daily. No acute
toxicity was found, dermatological toxity was minimal and
no liver function abnormalities were observed. One case
(from the 300mg group) of impaired night vision was
observed. For this reason the recommended dose for chemo-
prevention phase III trials of HPR is 200mg per day.
On 1 March 1987, a randomised phase III trial (treated
group vs control group) started to evaluate the effectiveness
of HPR in preventing contralateral breast cancer in patients
already operated on for a mammary malignant carcinoma.
On 30 September 1988, the total number of patients
randomised was 1,092 (HPR group 562, control group 530).
Up to now, tolerability has been good and compliance is
over 90%. One case of contralateral breast cancer has been
observed in the control group.
Dietary measures in the prevention of breast cancer
P. Greenwald
Division of Cancer Prevention and Control, Department of
Health and Human Services, National Institute of Health,
Bethesda, MD 20892, USA.
A reduced breast cancer risk after a low fat diet is suggested
by experimental studies in rodents and by human epidemio-
logical studies. The incidence and multiplicity of mammary
tumours in rodents is increased when fat is fed after the
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administration of a carcinogen, suggesting a promotional
effect for dietary fat. This adverse effect of fat is most clear
for the animals on a high fat, high calorie (ad libitum) diet as
compared to those on a low fat, restricted diet. While the
relative contributions of fat and calories are viewed
differently by various investigators, studies are consistent in
showing that dietary fat and total caloric intake in rodents
both have tumour-enhancing effects. Type of fat is also a
subject of current research. In rodent studies, high levels of
saturated and polyunsaturated fat increase risk provided that
a minimum amount of polyunsaturated fat is present to
provide essential fatty acids. Monounsaturates and fish oils
may not have this adverse effect.
Epidemiological evidence in support of the fat hypothesis
comes from 'natural' experiments - that is, studies of
international variation of breast cancer in association with
diet, migration studies and time trend studies within
countries. Countries with a high fat intake, such as the
United States, have five to six times as much breast cancer
as countries with a low fat intake, such as Japan. Japan gets
15% of calories from fat compared to 38% for the United
States. Migration studies show that when Japanese move to
Hawaii or when Italians move to Australia and adopt a high
fat diet, their breast cancer rates go up. Trends in Japan also
show this association: from 1955 to 1975 there was a 2.5-fold
increase in fat intake and a 50% increase in breast cancer. In
these studies, it is not completely possible to separate out
some linked factors. For example, people who eat more fat
tend to eat more calories and may be obese. These studies
are not very precise in suggesting in what period of life diet
is most important. Although migration studies indicate that
breast cancer risk changes during adult years, the
developmental teenage years could also be important.
Epidemiological case-control and cohort studies have given
inconsistent results about dietary fat and breast cancer. This
may reflect the limitations of these epidemiological studies in
measuring diet accurately and in identifying differences in
fairly homogeneous populations.
Future research needs to focus, in part, on clinical
metabolic studies, biochemical markers of dietary intake,
markers predictive of breast cancer occurrence and clinical
prevention trials. The United States National Cancer
Institute (NCI) believes that the present research base is
sufficient to make public recommendations now, while
further research is undertaken. NCI recommends that you
reduce fat intake to less than 30% of calories, choose from a
variety of food sources, including vegetables, fruits and
whole grains, and maintain desirable weight.




Chief Medical Officer, Department of Health & Social
Security, London, UK.
Screening and mammography is the only procedure that has
been shown to make a significant impact on mortality from
breast cancer. Even though the UK Trials of the Early
Detection of Breast Cancer were still in progress, the
government decided in the light of the publication in April
1985 of the Swedish two-counties study to ask Sir Patrick
Forrest to review the scientific evidence concerning breast
cancer screening and to propose a model for a national
breast cancer screening programme.
In February 1987 the Secretary of State announced the
publication of the Forrest report and the government's
funding of the recommendations: women aged 50-64 are to
be invited for mammographic screening every 3 years. In the
wake of the announcement the Department of Health has
established four training centres, established the Advisory
Committee on Breast Cancer Screening, organised the
necessary information technology for the programme,
investigated the equipment requirements, appointed a
training facilitator and produced guidelines on quality
assurance in screening mammography. In addition, the
Health Education Authority has been funded to produce
publicity for the programme and the Department of Health
is involved in the Subcommittee of the UK Co-ordinating
Committee on Cancer Research concerned with promoting
further research in breast cancer screening.
The recent results from the UK Trials of the Early
Detection of Breast Cancer, although not as good as the
Swedish results, if reproduced in the national programme,
could make an important impact on mortality from breast
cancer. The results do, however, emphasise the importance
of high attendance rates and the need for the screening
programme to be of the highest quality.
Tamoxifen prevention of breast cancer
T. Powles & J. Hardy
Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
Epidemiological and experimental evidence indicates that
oestrogens are involved in the carcinogenic promotion of
human breast cancer. This raises the therapeutic possibility
that endocrine intervention could prevent breast cancer. The
studies of breast cancer incidence following the atomic bomb
explosions in Japan in 1945 show that it takes more than 13
years to develop clinical breast cancer after carcinogenic
initiation. Clinical trial statistics indicate that 10,000 women
would be required in a trial to detect a 25% prevention
effect with at least a 50% compliance and a follow-up of 15
years. Furthermore, experiments with the DMBA tumour
show that continued endocrine intervention after initiation is
required in order to maintain prevention. The anti-
oestrogenic endocrine intervention would need to be easy
and well tolerated in order to maintain compliance over
many years. Tamoxifen, a powerful anti-oestrogenic, with
proven activity against breast cancer, has very low toxicity
and would be a suitable agent.
We have therefore started a feasibility study to test
whether it is possible to mount a tamoxifen prevention trial
for high risk women.
The Leah Lederman Memorial Lecture
Screen detected breast cancer
M.F. Spittle
Meyerstein Institute of Radiotherapy and Oncology,
Middlesex Hospital, London WIN 8AA, UK.
The government implementation of the Forrest Report will
produce a cohort of patients with breast cancer, with a
spectrum of disease different from those usually encountered.
Although the prevaleAce screen will detect breast cancer in
all stages, the incidence screens are expected to produce a
high proportion of early and small cancers. The management
of patients with carcinoma in situ is a dilemma. Lobular
carcinoma in situ when impalpable is rarely shown by
mammography and yet may be incidentally detected by
screening. Its discovery represents an increased threat of the
subsequent development of breast cancer of 20% over 20BACR/BIR/RSM JOINT WINTER MEETING 817
years. This subsequent cancer may affect either breast.
Although wide excision seems the treatment of choice, trials
of adjuvant therapy may be appropriate. Thirty per cent of
screen-detected cancers may be carcinoma in situ. Small
series of patients with these usually impalpable lesions are
available to consider treatment. As axillary nodes are almost
never involved, the prognosis is excellent. Mastectomy cures,
lumpectomy and irradiation give the same local result as
irradiating early invasive cancer. Local recurrence occurs in
less than 10% and may be treated without prejudicing
survival by further local excision or mastectomy. Wide local
excision may be an equally effective primary treatment.
Especially in view of the cost of the screening programme
and the work involved, the contribution of treatment, both
surgical and radiotherapeutic or innovative, must be
evaluated from the outset by national controlled trials. This
is an exciting opportunity to offer women specific evidence
on which to base their treatment decisions.
Symposium on Human Cancer Genetics
Clinical and fundamental aspects of heterogeneity in the
FAMMM syndrome
W. Bergman', M. Crijns1, P. Watson2 & H. Lynch2
1Department of Dermatology, University Medical Centre,
2300 RC Leiden, The Netherlands and 2Hereditary Cancer
Institute, Creighton University, Omaha, NE 68278, USA.
The FAMMM sydrome consists of the familial occurrence of
cutaneous malignant melanoma and atypical nevi (dysplastic
nevi) and is inherited as an autosomal dominant trait. The
spectrum of clinical signs characterising the phenotype of the
DNS ranges from minimal to obvious manifestations.
Several cases will be presented. The gene is also rather
frequently non-penetrant (0.27) in our 10 extended
FAMMM pedigrees comprising 520 family members. There
is a question as to whether non-melanoma cancers are
associated in some but not all FAMMM families. To focus
upon the subset of families with associated systemic cancer,
families with at least one case of pancreatic cancer were
selected for inclusion; to correct for this selection rule, one
case of pancreatic cancer per family was disregarded in the
statistical analyses. In three of the families, 81 cases born
between 1880 and 1950 were included in the study, based on
dysplastic nevus/melanoma status: 24 affected, 16 obligate
gene carriers and 41 first degree relatives. Observed cancer
incidence was compared to expected cancer incidence, based
on incidence in the Netherlands. After correction for
ascertainment, we observed significant excesses of pancreatic
cancers (P<0.02) and other systemic cancers (P<0.01) in
these three families. There were 9 pancreatic carcinomas
among the 81 cases in the three families and about one-third
of the cases were affected with systemic cancer. Similar
cancer site heterogeneity has been observed in most cancer-
associated genodermatoses.
The molecular genetics of multiple endocrine neoplasia
type 2
C.G.P. Mathew, D.F. Easton, H. Telenius, K. Chin &
B.A.J. Ponder
Institute of Cancer Research, Sutton, Surrey SM2 5NG,
UK.
Multiple endocrine neoplasia type 2a (MEN 2a) is an
autosomal dominantly inherited cancer syndrome associated
with medullary thyroid carcinoma, phaeochromocytoma and
parathyroid hyperplasia. The gene for this disorder has been
mapped to the peri-centromeric region of chromosome 10 by
linkage analysis using polymorphic DNA markers (Mathew
et al., Nature, 1987, 328, 527; Simpson et al., Nature, 1987,
328, 528). We tested a series of chromosome 10 markers in a
large panel of MEN 2a families, and established that several
of these were linked to the MEN 2a gene at recombination
fractions of 5% or less. No evidence for genetic
heterogeneity was obtained. The new markers provide a
powerful and simple means of screening families for
MEN 2a gene carriers. They have also enabled us to narrow
the search for the gene to a relatively small chromosomal
region.
We have also investigated the mechanism of tumorigenesis
in MEN 2a by analysis of tumour DNA samples for somatic
loss of constitutional heterozygosity with markers from most
human chromosomes. Unlike retinoblastoma, MEN 2a
tumours were not associated with detectable deletions at the
locus of the inherited mutation. About one-third, however,
showed deletions on the short arm of chromosome 1. This
may represent a secondary event in the development of
endocrine neoplasia.
Molecular and developmental approaches to Wilms' tumour
V. van Heyningen
MRC Clinical and Population Cytogenetics Unit, Western
General Hospital, Edinburgh EH4 2XU, UK.
To identify the recessive gene implicated in the development
of Wilms' tumour (WT), we have exploited the existence of
associated chromosomal rearrangements. Most of these
rearrangements are constitutional deletions of varying length
around band p13 on chromosome 11. Using the techniques
of somatic cell genetics a number of new DNA markers for
the lip13 region have been isolated and mapped. With the
aid of the long range map now being constructed, we can
predict in which direction and how far we must 'walk',
'jump' or 'island hop' to reach the WT gene. One of the
most difficult problems in this 'reverse genetics' approach to
gene isolation is knowing when we have arrived. Insight into
normal kidney development and the aberrations which might
give rise to nephroblastoma must hold the answer. The
observed heterogeneity of tumour type and the variable
nature of the associated abnormalities suggest that we may
be dealing with a number of closely linked genes involved in
genitourinary development, or alternatively with a single
pleiotropic gene. The predicted function of any gene isolated
from the WT region will be examined with these
considerations in mind.
The 9th Gordon Hamilton-Fairley Memorial
Lecture
Hereditary cancers: clues to mechanisms of oncogenesis
A.G. Knudson
Institute for Cancer Research, Fox Chase Cancer Center,
Philadelphia, PA 19111, USA.
Most cancers occur in hereditary as well as non-hereditary
form. Although hereditary cancers are rare, they assume
importance out of proportion to their frequencies, partly
because they are so great a burden to some families, but
even more particularly because they have illuminated a
genetic mechanism that may be important for much non-
hereditary cancer.
The prototype of hereditary cancer has been the rare818 BACR/BIR/RSM JOINT WINTER MEETING
cancer of children, retinoblastoma. Genetic epidemiological
analysis led to a two-event model of its origin. The first
event could occur in either the germline or somatic tissue,
the second event always in the latter. The events were
conceived as effecting mutation or loss of both copies of a
particular gene. Mechanisms proposed for the second event
included local mutation, deletion, chromosomal loss, and
somatic recombination. The critical events in oncogenesis
were considered to result in a single gene defect, i.e. such
cancer genes display dominant inheritance of susceptibility
but recessive mechanism of oncogenesis. A critical test of
this hypothesis has been possible, following chromosomal
localisation of the retinoblastoma gene, the development of
syntenic DNA probes and the cloning of the gene.
Data on other cancers suggest that the retinoblastoma
gene belongs to a class of genes different from that of the
oncogenes. These other genes have been called recessive
oncogenes, tumour suppressor genes and anti-oncogenes.
They may operate not only in tumour initiation, but also in
tumour progression. Questions remain on the mechanisms of
their tissue specificities and their roles in histogenesis.
Ataxia-telangiectasia - a cancer-prone genetic disorder
associated with mis-repair of DNA strand scissions
R. Cox
MRC Radiobiology Unit, Harwell, Didcot, Oxon OXI]
ORD, UK.
Ataxia-telangiectasia (A-T) is a rare autosomal recessive
genetic disorder with childhood manifestations of
neuromotor dysfunction, immunodeficiency and
predisposition to T-cell neoplasia. Early findings of in vivo
hypersensitivity in A-T patients to therapeutic doses of
ionising radiation were followed by in vitro studies showing
that this hypersensitivity had a cellular basis which could be
consistent with a primary DNA-repair deficiency.
The biochemical and molecular bases of the putative
DNA-repair defect(s) in A-T have yet to be convincingly
resolved but selected studies will be described which suggest
an association between the A-T cellular phenotype, an
elevated frequency of misrepair of double strand scissions
and DNA topoisomerase II deficiency.
The possible consequences of the postulated repair defect
for immune functions and T-cell neoplasia in A-T will be
discussed.
Symposium on Tumour Localisation
Techniques for Diagnosis and Therapy
Use of single photon emission computed tomography
(SPECT) in oncology
R.J. Ott
Joint Department of Physics, Institute of Cancer Research
and The Royal Marsden Hospital, Sutton, Surrey, UK.
The development of SPECT using a rotating gamma camera
interfaced to an on-line computer system has allowed
multislice tomographic images of the in vivo distribution of
radiopharmaceuticals to be produced. Such images can be
used to make quantitative estimates of the uptake of such
agents in tumour and normal tissues. SPECT studies have
been carried out using tumour localising agents such as
monoclonal antibodies and metaiodobenzylguanidine to
determine the uptake of these agents in human tissues. These
studies allow approximate estimates of radiation doses to be
made if such agents are to be used therapeutically. Other
applications include the monitoring of tumour physiology
during treatment using agents such as Ga-67 citrate and Tc-
99m-HMPAO. All these applications will be reviewed to
evaluate whether the physical limitations of SPECT with a
gamma-camera allow significant contributions to be made to
the diagnosis and treatment of cancer. Special purpose
instruments designed for SPECT will also be reviewed.
Positron emission tomography in the characterisation and
treatment follow-up of brain tumours
M. Bergstr6ml, C. Muhr1, P.O. Lundberg' &
B. Langstr6m2
'Department of Neurology and 2Organic Chemistry, Uppsala
University, Uppsala, Sweden.
Positron emission tomography enables in vivo kinetic studies
with tracer substances labelled with shortlived positron
emitting radionuclides. We have used this technique with
substances labelled with "1C to diagnose and characterise
intracranial tumours before treatment as well as to follow
the results of medical treatments in these tumours.
In pituitary adenomas preliminary studies demonstrating
amino acid metabolism and dopamine D2-receptors were
able to discriminate well between on one hand prolactinomas
with high metabolism and high D2-receptor binding and on
the other hand null cell adenomas with lower metabolism
and low or negligible D2-receptor binding. During treatment
with the dopamine agonist bromocriptine the metabolism
decreased rapidly, within a few hours, in the prolactinomas,
indicating a favourable response. This was later accompanied
by a significant tumour size reduction. The technique was
also valuable in the clinical evaluation and treatment follow-
up in GH-secreting adenomas.
In the search for medical treatment alternatives in
meningiomas, PET offered a highly sensitive tool for
monitoring effects. During short treatment periods a few
medical alternatives were tested and especially interferon
demonstrated a favourable effect on this tumour with a 20-
30% decrease in the tumour metabolism. In longer follow-up
times stationary growth or size reductions have been noticed.
Localisation of radiolabelied monoclonal anti-CEA antibodies
and fragments in colon carcinoma, diagnostic and therapeutic
approaches
J.-P. Mach, F. Buchegger, A. Bischof-Delaloye,
S. Curchod, F. Mosimann, J.-C. Givel, J. Pettavel &
B. Delaloye
Institute of Biochemistry, University of Lausanne, Ch-1066
Epalinges, and Division of Nuclear Medicine, CHUV,
CH-1011 Lausanne, Switzerland.
Thirty-one patients with known colorectal carcinomas were
injected with Fab and F(ab')2 fragments from the
monoclonal anti-CEA antibody (MAb) 35 labelled with 3-
6mCi of 1-123 and tested by emission computerised
tomography (ECT) 6, 24 and 48 h after injection. All 23
primary tumours and local recurrences except one were
clearly visualised. Interestingly, 9 of these patients had
almost normal circulating CEA levels and 3 of the visualised
tumours weighed only 3-5g. Among 19 known metastatic
tumour involvements, 14 were correctly localised by ECT
(Delaloye et al., J. Clin. Invest., 1986, 77, 301).
Following encouraging results of tumour therapy in nude
mice, showing that intact and F(ab')2 fragments of anti-
CEA MAb labelled with therapeutic doses of 1-131 could
inhibit the growth of human colon carcinoma xenografts or
provoke tumour regression (Buchegger et al., Int. J. Cancer,BACR/BIR/RSM JOINT WINTER MEETING 819
1988, 41, 127), 7 patients were injected with two anti-CEA
MAbs, 35 and 25-B7 labelled with lOOmCi of 1-131. All
patients had liver metastases from large bowel carcinoma
and the radiolabelled MAb were injected into the hepatic
artery. The first 3 patients received F(ab')2 and the 4 last
ones intact MAb. None of the 7 patients showed any
significant side effect for a period of observation of 6-21
months, except for the last patient, who received two doses
of lOOmCi of intact 1-131 MAbs, and presented a severe
leuco- and thrombocytopenia which was easily controlled by
injection of allogeneic platelets. We observed good
localisation of intact 1-131 MAb in liver metastases,
documented by ECT, and tumour radiation doses of about
2,500rads per injection, but we have not yet obtained
definite evidence of tumour regression. The last 3 patients
had liver metastases of less than 80-120g, which could be
surgically resected 2 and 4 months after injection for two
patients, or successfully treated by intra-arterial
chemotherapy in the third patient. Two of these 3 patients
have now a normal CEA and no evidence of disease, 17 and
21 months after injection.
Prospects for neutron capture therapy
K.R. Durrant & C.B.T. Adams
Department of Radiotherapy and Oncology, and Neurological
Surgery, Churchill Hospital and Radcliffe Infirmary, Oxford,
UK.
Irradiation with low-energy neutrons of tissues containing
high concentration of boron-1O leads to the neutron-capture
reaction, with the production of very short-range densely
ionising particles. The range of these particles is of the order
of one cell diameter and there is little irradiation of non-
borated cells.
This reaction occurs within a limited neutron energy
range, and an intense neutron flux from a reactor is
necessary to be of practical value. Similarly the intracellular
boron concentration is critical.
Recent progress has been made in the selective boronation
of tumour cells, and in the production of intense neutron
energy fluxes of the optimum energy. For non-metastasising
tumours of limited radio-sensitivity such as malignant
gliomas, neutron-capture therapy offers the prospect of a
major involvement in therapeutic results.
Astatine-211 in cancer therapy
L.M. Cobb
Department of Experimental Pathology and Therapeutics,
MRC Radiobiology Unit, Harwell, Didcot, Oxon OXJJ
ORD, UK.
The main emissions following the disintegration of astatine-
211 are a-particles of either 5.9 MeV or, from the 211po
daughter, 7.45 MeV. This radionuclide is of interest in
targeted therapy because of the very significant cytotoxicity
of x-particles. Compared with the fl-particles of iodine-131
or yttrium-90 they will produce approximately 200 times the
number of DNA double strand breaks per nuclear traversal.
The isotope, which has a half-life of 7.2h and is cyclotron-
produced, is at present only used experimentally. When
conjugated to a tumour-specific monoclonal antibody (MRC
OX7) 21'At produced 50% cure in mice bearing a T-cell
lymphoblastic lymphoma (Harrison et al., 1987, NCI
Monogr., 3, 157). The therapeutic potential has also been
demonstrated for astatine-211 when linked to 2-methyl-1,4-
naphthoquinol diphosphate or methylene blue, both of
which accumulate in certain tumours (Brown, I. et al., 1986,
Appl. Radiat. Isot., 37, 789).
There may be a place for 211At in thyroid therapy without
the need for a targeting agent. Astatine is a halogen and, like
iodine, is concentrated by the thyroid gland, where it can
produce pathological changes (Cobb, L.M. et al., 1988,
Human Toxicol., 7, 529). When mice bearing xenografts of
human thyroid tumour were injected with 211At as sodium
astatide the radionuclide localised in significant amounts in
both follicular and anaplastic carcinomas (Cobb L.M. et al.,
1989, Radiotherap. and Oncol., 3, 203), indicating its
potential value in patients where iodine-131 is not expected
to reach an effective concentration.
Abstracts of members' proffered
papers
Increased incidence of breast cancer in first degree relatives
of newly diagnosed breast cancer patients
S.A. Wallace', J.M. Birch', D. Teare', M. Harris',
A. Howell' & R.A. Sellwood2
'Departments of Epidemiology, Oncology and Pathology,
Christie Hospital, Manchester, and 2Surgery, Withington
Hospital, Manchester, UK.
There have been few unbiased, comprehensive surveys of
breast cancer (BC) risk among relatives of BC patients and
none from the UK. Therefore 432 consecutively diagnosed
BC patients were interviewed to assess the incidence of BC in
first degree relatives. Reported BCs were confirmed by
histological review. 422 mothers, 544 sisters and 396
daughters were included in the analysis. Expected numbers of
BCs, calculated from age specific incidence rates were
compared with observed numbers. Overall there was a
significant excess (relative risk (RR) 1.6; Poisson probability
(P)<0.001) which was higher for sisters (RR 1.9, P<0.01)
and daughters (RR 5.6, P<0.01) than mothers (RR 1.3,
P=0.2). First degree relatives were stratified according to the
following proband characteristics: age, menopausal status,
laterality, histology and hormone receptor status. Expected
numbers of BCs were calculated for each respective
subgroup. Factors in the proband associated with high BC
risk to relatives were: premenopausal status (RR 2.6,
P<0.001), age <50 (RR 2.7, P<0.001), unilateral left BC
(RR 2.1, P<0.001), ductal carcinoma (RR 1.7, P<0.001), and
oestrogen receptor positive (ER+) (RR 1.7, P<0.01).
Bilaterality in probands did not confer high BC risk to their
relatives (RR 1.2). Highest risk was seen in sisters of patients
age <50 (RR 5.4, P<0.001), daughters of patients with left
BC (RR 8.9, P<0.001), daughters of patients with lobular
carcinoma (RR 10.5, P<0.03) and daughters of patients with
ER+ tumours (RR 8.5, P<0.01). We conclude that analysis
of clinical characteristics in BC patients may be of use in
selecting high risk women for screening from among their
relatives and may indicate suitable subjects for laboratory
investigations of genetic breast cancer.
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Essential fatty acids inhibit breast cancer
G.A. Pritchard, R.E. Mansel & L.E. Hughes
Department of Surgery, University Hospital of Wales,
Cardiff CF4 4XN, UK.
High levels of dietary fat are implicated in the pathogenesis
of human breast cancer. The type of fat as well as the
quantity is important. We have studied the effect of
supplementary dietary fatty acids on the growth of human
MCF7 breast tumours in athymic mice. Results are shown in
the table.
Primrose oil and fish oil are rich in polyunsaturated
essential fatty acids (y-linolenic acid 10%, eicosapentaenoic
acid 28%) and inhibited tumour growth. Olive oil had no
effect.
Several national groups in the USA have recommended
halving dietary fat intake to reduce breast cancer risk. We
would suggest that this be coupled with an increased balance
of essential fatty acids.
Tumour weight (mg)
Interquartile
Diet n Median range P (Mann-Whitney)
Control 24 271 149-453
5% olive oil 24 213 158-375 0.34 n.s.
5% primrose
oil 24 133 37-297 0.009
5% fish oil 24 70 19-205 0.001
The effects of a low-fat diet on serum oestradiol and serum
prolactin levels
I.L. Crighton', M. Dowsett2, M. Hunter3, C. Shaw3 &
I.E. Smith'
'Department of Medicine, 2Department of Biochemical
Endocrinology, and 3Department of Dietetics, Royal
Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
There is a good epidemiological evidence associating per
capita fat intake with the incidence of breast cancer
worldwide (Wynder et al., 1986, Cancer, 58, 1804). Changes
in fat intake may modify levels of circulating hormones
(Rose et al., 1987, JNCI, 78, 623; Ingram et al., 1987, JNCI,
79, 1225), and thereby influence the risk of developing breast
cancer.
For our study 18 pre- and 20 post-menopausal volunteers
were recruited. After an initial dietary assessment and
baseline blood sampling the volunteers were commenced on
a low-fat diet (approx. 20% calories from fat). Blood
samples were collected weekly for 4 weeks, and monthly
thereafter for as long as the diet was continued. Fat content
of the diet was assessed monthly by seven-day dietary
records. The blood samples were assayed for serum prolactin
(Prl) and oestradiol (E2) by radioimmunoassay. The results
are shown below.
None of above differences are statistically significant.
x+s.e.m. (n) Base After 4 weeks
Post-menopausal
Prl (IU/l) 109.5+12.3 (20) 97.2+8.2 (20)
E2 (pmo!/l) 35.2+10.2 (20) 25.9+5.9 (20)
Premenopausal
Prl (IU/1) 152+15 (18) 157+17.3 (18)
E2 (pmol/1) 249+35.5 (14) 434+106.2 (14)
These preliminary studies have not demonstrated any
significant changes in serum E2 and/or Prl levels as a result
of a short-term low-fat diet. Further investigation into the
long-term effects is in progress.
Hormonal enhancement of the actions of cytotoxic drugs on
breast cancer cells
N.A. Shaikh', A.M. Owen2, M.W. Ghilchik' &
H. Braunsberg2
'Breast Clinic and 2Department of Chemical Pathology, St
Mdry's Hospital and Medical School, London W2 IPG,
UK.
Clinical studies have suggested that pretreatment with
oestrogen (cf. Harmsen & Porsius, 1988, Eur. J. Cancer Clin.
Oncol., 24, 1099) or progestogen, possibly potentiated by
oestrogen (Ghilchik et al., 1987, Br. Med. J., 295, 1172) may
enhance the beneficial effects of cytotoxic drug
combinations. To investigate these claims and identify the
drugs involved we have studied possible hormone/drug
interactions in cultured human breast cancer cells. Using
MCF-7 cells and a subline (MCF-7M) which does not
respond to the growth-inhibitory action of medroxypro-
gesterone acetate (MPA), we have obtained convincing
evidence that immediate pre-treatment with either oestradiol
(E2), 1 nM 24h, or MPA, 10 to 40nM 48h, can enhance the
cytotoxic actions of 24h exposure to methotrexate (MTX),
vincristine (VCR) and adriamycin (ADR). The effects of
MPA appear to be independent of its growth-inhibitory and
glucocorticoid actions. Experiments conducted so far suggest
that exposure to E2 before MPA treatment potentiates the
effects of MPA on responses to MTX and ADR, but not
VCR, while E2 alone under these conditions had no effect.
The use of MPA, or sequential oestrogen and MPA,
pretreatment in conjunction with cytotoxic drug offers much
promise and deserves full clinical assessment.
Evaluation of an mRNA selectively expressed in human
breast cancer
Y.A. Luqmani, R. Skilton, R. McClelland &
R.C. Coombes
Clinical Oncology Unit, St George's Hospital Medical
School, London SW17 ORE, UK.
In an attempt to identify potential breast tumour markers,
we have performed differential hybridisation with mRNA
from normal and malignant breast tissue using a breast
cancer cDNA library. One of the clones isolated, a 250b.p.
cDNA (Md2), was found to hybridise to a 6-700 nucleotide
mRNA in 46% of 46 infiltrating ductal carcinomas.
Expression was seen mainly in a subset of oestrogen receptor
(ER) positive cancers but not in normal breast. Sequence
data showed complete homology with the 3' end of the pS2
gene (Jakowlew et al., 1984, Nucl. Acids Res., 12, 2861).
In order to study its cellular localisation we used 35S-
labelled Md2 for in situ hybridisation to frozen sections. We
observed specific autoradiographic signals over the tumour
cells of breast cancers with no significant reaction over
stromal or vascular elements and only very rarely were
grains seen over normal ductal epithelia above background.
To determine whether measurements of Md2 mRNA
could be of value in predicting response to therapy we
examined a group of 15 patients who had undergone
primary endocrine treatment for recurrent disease. We found
that expression of Md2 message in the primary tumour
correlated well with the subsequent response of the patients
to therapy (P=0.02). Its predictive value was the same asBACR/BIR/RSM JOINT WINTER MEETING 821
that provided by ER status: both measurements predicted
outcome correctly in about 80% of this group. In view of its
greater abundance, measurement of Md2/pS2 message could
be a useful marker if these initial findings are consistent over
a larger patient group.
Development of a mouse monoclonal antibody against human
urinary epithelial mucin for studies in breast cancer
M.R. Price, J.A. Pugh, A. Clarke, M. Sekowski,
C. O'Sullivan, E. Jacobs & J.F.R. Robertson
Cancer Research Campaign Laboratories, University of
Nottingham, and City Hospital, Nottingham, UK.
Human urine is an abundant source of a high molecular
weight polymorphic epithelial mucin, which is expressed by
breast cancer and other carcinomas as well as on the luminal
surfaces of normal glandular epithelia. The IgM anti-breast
carcinoma monoclonal antibody, NCRC-l1, reacts with this
mucin, and an NCRC-1 1 antibody immunoadsorbent
column was employed for its bulk purification directly from
normal urine. The material isolated was used as the
immunogen to produce 'second generation' monoclonal
antibodies to complement the range of reagents reactive with
breast carcinomas and available for further therapeutic and
diagnostic applications. One antibody, C595 - an IgG3
antibody - was selected for this purpose. C595 reacted with
mucins from breast and ovarian carcinomas, as well as with
antigen from normal human urine and with material elevated
in breast cancer patients' sera. The overall profile of
reactivity of the new IgG monoclonal antibody, prepared
against urinary mucin, was similar to that of the original
IgM anti-breast carcinoma antibody, NCRC-11.
The strategy adopted in this investigation illustrates an
approach for developing new customised antibody reagents
with properties, such as class, subclass or fine specificity,
which may be distinct from those of the 'parent' antibody.
from APC patients provides evidence in support of
Knudson's hypothesis.
Homozygous deletions of llpl3 markers in Wilms' tumour
DNAs
R. Wadey, B. Buckle, J. Cowell & J. Pritchard
ICRF Laboratory of Molecular Oncology, Institute of Child
Health, Guildford St., London WCIN, UK.
The association between aniridia and Wilms' tumour (WT)
with constitutional heterozygous deletions of the short arm
of chromosome 11 (1lp)- indicates the location of a WT
predisposition gene (Wg). The shortest region of overlap for
these deletions involves part of band llpl3. The isolation of
the retinoblastoma (Rb) predisposition gene was facilitated
by the presence of small homozygous deletions in a small
percentage of Rb tumour DNAs. To identify any similar
deletions in WT we used four recently isolated llpl3
sequences to probe primary WT DNAs. Two of these probes (p9RHD6.5 and DlIS87) were found to be homozygously
deleted in the same tumour (GOS 129). Neither of the other
two probes (NBSC 12 and p56H2.4) were deleted or
rearranged in any of the tumour DNAs tested.
In order to assign chromosome 11 markers to different
regions within the llpl3 region we isolated three 1lp deletions in somatic cell hybrids and characterised the
position of the breakpoints using Ilp markers including CAT and FSH,B (probes for the catalase and fi FSH subunit,
respectively). Using these hybrids three of the above probes (p9RHD6.5, Dl1S87 and NBSC 12) were mapped to the
distal region of llpl3 between CAT and the aniridia locus
(Ag). p56H2.4 was found to map to the proximal region of
Ilpl3 between Ag and FSH3.
We are characterising GOS 129DNA further, using flanking polymorphic Ilp markers and pulse field gel electrophoresis and also constructing a Lambda library of
GOS 129 DNA to try to isolate a clone spanning the
deletion.
Chromosome 5 allele loss in familial and sporadic colorectal
adenomas
M. Rees', S.E.A. Leigh', J.R. Jass2 & J.D.A. Delhantyt
'Galton Laboratory, University College London, 4
Stephenson Way, London NW] 2HE, and 2Department of
Pathology, St Mark's Hospital, City Road, London ECIV
2PS, UK.
DNA extracted from familial and sporadic colorectal
neoplasms was compared with constitutional DNA using a
range of hypervariable locus specific probes to assess the
extent of allele loss during conversion to malignancy.
Chromosome 5 allele loss was observed in 23% ofcarcinoma
samples, as previously found by others (Solomon et al.,
1987, Nature, 328, 616; Okamoto et al., 1988, Nature, 331,
273). However, we have been able to show for the first time
loss of the D5S43 locus in adenomas from 20% of patients,
the great majority of whom had the precancerous condition,
adenomatous polyposis coli (APC). These results suggest
significant genetic changes involving chromosome 5 are
occurring in benign adenomas. Probes for chromosome 1
(loci DlS7 and DIS8) and for chromosome 7 (loci D7S21
and D7S22) revealed no notable alterations in the adenoma
samples. Complete loss of alleles for loci on chromosome 7
was not observed in carcinomas but reduced intensity of one
parental allele was found in 3 specimens one of which was
known to have multiple copies of this chromosome. Results
using probes for chromosome 1 suggest that deletion of the
DIS7 or DlS8 loci is not a common event in colorectal
carcinogenesis. Loss of chromosome 5 alleles in adenomas
Multiple mRNA species for GGT appear to be transcribed
from a single gene
S.A. Griffiths & M.M. Manson
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM5 4EF, UK.
Gamma glutamyl transpeptidase (GGT) is a plasma membrane-bound heterodimeric glycoprotein with tissue-
specific expression during normal development and
carcinogenesis. GGT is induced focally in rat liver by hepatocarcinogens and also periportally after treatment with
the antioxidant ethoxyquin (EQ).
We have shown that the GGT mRNA induced in rat liver
(2.4kb) appears larger than the mRNA in normal rat kidney
(2.2kb). In order to study the expression of these two GGT
mRNA species, we prepared a cDNA library in Agt 10 from
F344 rat liver treated with EQ (0.5% in the diet for 23
weeks). The library was screened using a probe containing
two thirds of the Wistar rat kidney GGT cDNA (Laperche
et al., 1986, PNAS, 83, 937). We isolated a clone of 2.2kb
which contained an internal Eco RI site and subcloned the
two Eco RI fragments of 1.4kb and 0.8kb into M13 for
sequencing.
Analysis revealed a sequence of 2,054bp, plus 22 bases of
the poly A tail, containing a reading frame of 1,704bp, a 5'
untranslated sequence (UTS) of 203bp and a 3' UTS of
147bp. The predicted amino acid sequence of induced rat
liver GGT agrees with that of the rat kidney GGT with822 BACR/BIR/RSM JOINT WINTER MEETING
minor exceptions (Laperche & Guellaen, personal
communication). Both sequences predict a protein of
identical size. Southern blot data indicate a single gene for
GGT, which, together with the divergence in the 5' UTS of
our liver GGT cDNA compared with the kidney cDNA,
suggest differential splicing and the possibility of different
promoters for tissue specific expression of GGT.
S.A.G. was supported by a grant from AICR. We thank
J.A. Green for advice on computer analysis and P. Swann
for synthesising oligonucleotides.
Circulating lymphocyte subpopulations and NK cell activity
in the rat model of azoxymethane induced colon neoplasia
K.M. Rigg, B.K. Shenton, T.W.J. Lennard &
R.M.R. Taylor
Department of Surgery, The Medical School, Newcastle
upon Tyne NE2 4HH, UK.
The azoxymethane induced colonic tumour in rats is a
helpful model for the study of human colorectal cancer. We
examined the effect of rat intestinal neoplasia on circulating
lymphocyte subpopulations and natural killer (NK) cell
activity. Twenty-four male Sprague-Dawley rats weighing
188+21 g were injected with 15mgkg- I azoxymethene s.c.
weekly for six weeks. A control group of 24 weighing
187 +20g were injected with saline. At 26 weeks the rats were
anaesthetised in pairs and venesected. The azoxymethane
group yielded 96 colonic and duodenal tumours.
Lymphocytes were separated and stained with a panel of
monoclonal antibodies for T-cells (OX19), T suppressor/
cytotoxic (OX8), T helper (W3/25) and interleukin-2 receptor
(OX39). Analysis was performed by flow cytometry. NK
activity was determine by a 4h 5ICr release cytotoxicity
assay using labelled YAC-l cells as targets at varying


























Control % killing Tumour % killing
Subset median (range) median (range)
OX19 53(11-99) 32(7-64)
OX8 43(7-93) 20(5-55)
W3/25 38 (5-57) 14(1-47)
OX9 30 (2-53) 9(1-29)b
ap<0.04; bp<0.01, Mann-Whitney U test.
NK activity is reduced in the tumour bearing rat and is
associated with fewer circulating T-cells. These immune
defects associated with rat intestinal neoplasia provide a
suitable model for the testing of specific immunomodulators.
Nucleolar organiser regions (NORs) in dysplastic lesions and
squamous cell carcinomas of the oral mucosa
S. Chungpanich & C.J. Smith
Department of Oral Pathology, University of Sheffield, 31
Claremont Crescent, Sheffield SJO 2TA, UK.
A silver staining technique for NOR-associated proteins has
been shown to distinguish benign from malignant lesions in
various sites. This study aims to determine whether the
technique predicts malignant potential in dysplastic lesions of
oral mucosa by comparing AgNORs in groups of these
lesions, in oral cancer and in normal mucosa. The original
method of Ploton et al. (Histochem. J., 1986, 18, 5) has been
modified by staining at 4°C. The material comprised 27
examples of oral epithelial dysplasia (OED), 10 oral
squamous cell carcinomas (OSCC) and 10 controls of
normal oral mucosa (NOM); all were formalin fixed and
paraffin embedded. The OED specimens were subdivided
into groups: 10 lesions coexisting with carcinoma (group A),
7 lesions with (group B) and 10 lesions without (group C)
malignant development over the succeeding five years. The
number of AgNORs per nucleus was counted under a x 100
lens separately in the basal and in the deepest three supra-
basal layers (100 consecutive cells in randomly selected fields
of each layer). In the basal layer, there were no statistically
significant differences between mean AgNOR counts in
OSCC (4.59+0.93) and any group of OED (A=4.35+0.63,
B=5.26+ 1.09, C=5.30+ 1.63), nor between the OED groups
themselves. However, all had significantly higher counts
(P<0.05) than NOM (3.45+0.89). In the suprabasal layers,
the mean AgNOR counts in groups B (6.35+1.19) and C
(6.63 + 1.94) were significantly higher (P<0.05) than in
OSCC (4.98+1.22) and NOM (4.59+0.82); those in group A
(5.22+1.94) were similar to carcinoma. Again there were no
statistically significant differences between the three OED
groups. The mean AgNOR counts do not appear to be
reliable indices for assessing malignant potential of OED.
Expression of p62 c-myc in the prognosis of colorectal
cancer
S. Rowley, J.P. Neoptolemus, I.A. Donovan &
M.R.B. Keighley
Department of Surgery, Dudley Road Hospital and
University of Birmingham, UK.
Expression of the c-myc oncogene has been shown to be of
some significance in the prognosis of carcinoma of the breast
and cervix.
We have quantified the c-myc protein product (p62 c-myc)
in colorectal cancer using archival paraffin embedded
material. A double labelling technique was used on extracted
nuclei with a mouse monoclonal antibody to p62 c-myc
(MYC-1 6E10) and a second fluoroscein labelled rabbit
antimouse immunoglobulin. DNA in the nuclei was
counterstained with propidium iodide. The levels of p62
c-myc were quantified using a flow cytometer and expressed
as fluorescence units (FU).
p62 c-myc was compared to stage and outcome in 47
patients. There was no relationship to Dukes stage: stage A
(n=6, mean 13.5 FU, range 0-45); stage B (n=21, 44.8, 0-
150); stage C (n= 13, 60, 13-201); stage D (n=7, 32, 3-68).
Levels of p62 c-myc less than 20 FU were associated with
significantly improved survival over 5 years (log rank
analysis x2 =4.76, d.f.l, P<0.05).
These results suggest that p62 c-myc expression may be a
prognostic index for colorectal cancer.
Frequency of serum tumour marker monitoring in patients
with non-seminomatous germ cell tumours
M.J. Seckl, G.J.S. Rustin & K.D. Bagshawe
Department of Medical Oncology, Charing Cross Hospital,
London W6 8RF, UK.
In patients relapsing on surveillance following orchidectomy
for stage I non seminomatous germ cell tumours, it is
essential that treatment is initiated before they developBACR/BIR/RSM JOINT WINTER MEETING 823
advanced disease with a poor prognosis. Patients who start
chemotherapy with levels of human chorionic gonadotrophin
(HCG) > 1,000i.u.1-1 and/or alpha-fetoprotein (AFP) level
>500kuI1 have been shown to have a worse prognosis
than patients with lower marker levels (Lancet, 1985, ii, 8).
We studied 64 patients between 1968 and 1987 with rising
serial tumour markers in an attempt to predict the time
taken for HCG or AFP to rise to poor prognostic levels.
Rates of marker increase could have resulted in adverse
levels in 2 patients (3.1%) within 14 days, in 8 patients
(12.5%) within 28 days and in 16 patients (25%) within 6
weeks. This suggests that initially, weekly marker estimations
should be performed on stage I surveillance patients. The
extra cost to a specialist follow-up laboratory of weekly as
opposed to the usual monthly marker measurements will be
less than £33,600 for every 400 patients on surveillance. One
extra patient is likely to be cured for this sum.
Tumour-associated trypsin inhibitor (TATI) as a marker of
ovarian cancer
J. Fisken, R.C.F. Leonard & J.E. Roulston
University Departments of Clinical Chemistry and Clinical
Oncology, Royal Infirmary, Edinburgh EH3 9YW and
Western General Hospital, Edinburgh EH4 2XU, UK.
TATI is a 6kD peptide, first isolated from the urine of a
patient with ovarian serous cystadenocarcinoma. Putative
roles include tumour protection and, conversely, host defence
against tumour invasion. Elevated TATI has been found in
urine, serum and tissue extracts from patients with
gynaecologic malignancy. Particularly high levels occur in
serum and cyst fluid from patients with mucinous ovarian
carcinomas, which tend to be poor or non-secretors of
CA125. A role of TATI in the management of ovarian
mucinous cancer has therefore been suggested (H. Halila et
al., Br. J. Cancer, 1988, 57, 304).
We assayed serum CA125 and TATI in 359 serial samples
from 142 ovarian epithelial cancer patients. Of those
currently assessed, 105 patients were followed up for 1-44
months (median 11 months). Overall sensitivity and
specificity for TATI were 53% and 84% respectively, greater
values than those obtained for PLAP (placental-like alkaline
phosphatase) in the same patient cohort (J. Fisken et al., J.
Clin. Pathol., in the press). Sensitivity was 9%, 25%, 54%
and 73%, specificity was 88%, 88%, 80% and 100% for
FIGO disease stages I, II, III and IV respectively. TATI
assay detected I true positive (TP) result in 3 stage III
patients where CA125 was false negative (FN), while 3
stage IV patients had consistently TP TATI levels
(>3 x upper limit of normal) when CA125 was FN (1
mucinous, 1 endometroid and 1 serous papillary
adenocarcinoma). TATI was positive in a further 4 patients,
with negative CA125 levels, needing further clinical
evaluation. Our preliminary analyses indicate that TATI may
provide useful additional information in management of
certain patients with ovarian cancer.
Potent inhibition of oesophageal metabolism of
methylbenzylnitrosamine, an oesophageal carcinogen, by
higher alcohols present in alcoholic beverages
V.M. Craddock
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM5 4EF, UK.
Consumption of alcoholic beverages is associated with
oesophageal cancer, but ethanol per se has not been shown
to be carcinogenic in animal experiments. Certain
nitrosamines to which man is exposed are the most potent
oesophageal carcinogens known. The concept that the action
of alcohol is mediated through an effect on nitrosamine
metabolism has been studied previously, but work was done
mainly with nitrosamines not especially carcinogenic for
oesophagus, and with liver microsomes, although each tissue
has its distinctive spectrum of cytochrome P450 isozymes.
Ethanol has been the alcohol studied, but cancer risk
depends not only on the overall ethanol intake, but also on
the type of alcoholic beverage. Apple brandy presents an
exceptionally high risk, followed by other spirits, wine and
beer. Apple-based alcoholic drinks contain unusually high
levels of higher alcohols, grape brandies and whisky contain
less, with much lower concentrations in wine and beer.
Cancer risk is proportional to intake of higher alcohols.
The effect of ethanol and a major higher alcohol, 2-
methylbutanol (2Mb), on metabolism of methylbenzylnitro-
samine (MBzN), a potent oesophageal carcinogen, was
studied using oesophageal and liver microsomes. 2Mb was
approx. 1,000 times more potent an inhibitor than was
ethanol.
The significance of the competitive inhibition could be its
implication that the 2Mb is metabolised much more rapidly
than is ethanol, presumably to form toxic aldehydes. 2Mb
but not ethanol increased cell replication in the oesophagus.
As with neonatal animals, increased vulnerability to nitro-
samines is likely to be due to the higher rate of DNA
replication, and to occur in spite of reduced nitrosamine
metabolism, not because of it.
The use of sustained release leuprorelin in advanced
carcinoma of the prostate
R.T.D. Oliver, A.J. Neal, M. Caulfield & S. Heard
Department of Medical Oncology, The London Hospital,
London, UK.
Leuprorelin acetate (Leuprolide, Lederle Laboratories) is a
synthetic gonadotrophin releasing hormone analogue.
Twenty consecutive referrals with previously untreated
metastatic carcinoma of the prostate, aged 47-80 years, were
recruited into a non-randomised phase II trial between
February 1987 and February 1988, to assess the efficacy and
toxicity profile of this drug in a sustained release
preparation. Patients received a monthly subcutaneous
injection of 3.75mg in 2ml of diluent via a 23 gauge needle
until disease progression. To date, 12/20 remain on
Leuprolide, 4/20 have died and 4/20 have been withdrawn
due to disease progression (median time on study for all
patients=10 months. One of 20 was castrate on starting
treatment, and the remaining 19/20 attained castrate levels of
testosterone (13 within 4 weeks). Nineteen of 20 had an
elevated prostatic acid phosphatase, 14 attaining normal
values. Fourteen of 20 had an abnormal isotope bone scan,
and of these 7 attained a partial response. Eight of 20 had
extraskeletal metastases, with 1 complete and 6 partial
responses. Overall, 14/20 attained a partial response (NPCP
criteria) at some point in the study. There were no serious
injection site reactions, and no haematological or bio-
chemical disturbances of note. We conclude that sustained
release Leuprolide is a safe, effective and convenient
alternative to agents currently available in the treatment of
advanced carcinoma of the prostate.
Preliminary study of aromatase inhibitor CGS16949A in
advanced post-menopausal breast cancer
R.C. Stein', M. Dowsett2, J. Davenport', A. Hedley1 &
R.C. Coombes'
'Clinical Oncology Unit, St George's Hospital Medical
School, London SW17 ORE, and 'Endocrine Department,
Chelsea Hospitalfor Women, London SW3 6LT, UK.
CGS16949A, a potent non-steroidal competitive aromatase
inhibitor, has been used to treat 31 post-menopausal women824 BACR/BIR/RSM JOINT WINTER MEETING
with locally advanced or metastatic breast cancer. Doses of
0.3mg BD, 1 mg BD and 2mg BD orally were used. The
median age of patients was 70 (range 51-90). Sixteen
patients had ER positive carcinomas; the ER status of 12
was unknown. Nine patients (out of 17 who were assessed)
had responded to previous endocrine therapy.
Twenty-eight patients, treated with CGS16949A for a
median of 4 months (maximum 8) have been assessed for
response by UICC criteria. Five patients all treated with
1 mg BD have responded and disease has stabilised in 15
patients. Disease sites in responding patients were soft tissue
(4), bone (1).
Side effects were reported by 10 patients. One patient
treated with 0.3mg BD developed a vasculitic rash
necessitating withdrawal from treatment. Two patients
treated with 2mg BD had troublesome nausea. Other side
effects were mild and transient and included flushing,
headache, giddiness, lethargy and disturbance of taste.
Oestradiol (E2) and oestrone level measured in 11 patients
treated with both 0.3mg BD and 1 mg BD were significantly
suppressed after 2 weeks at both dose levels: E2, pre:
27.0+4.0, 0.3mg: 16.2+3.4, 1 mg: 9.9+1.7pmoll-1
(x+s.e.m.). Serum aldosterone levels were significantly
(P<0.02) reduced at 1mg BD: pre: 278+30, 0.3mg: 249+ 18:
1mg: 198+24 pmoll-1, n=10. No change in gonadotro-
phins, SHBG and other adrenal hormones occurred.
Endocrine data for 2mg BD are not yet available.
Conclusions: CGS16949A is a clinically effective
aromatase inhibitor. Endocrine data indicate that 1 mg BD
is a more effective dose than 0.3 mg BD. Non-specific
adrenal suppression may be a problem at higher doses.
4-Hydroxyandrostenedione alone and in combination with
Zoladex in premenopausal breast cancer
R.C. Stein', M. Dowsett2, A. Hedley' & R.C. Coombes'
'Clinical Oncology Unit, St George's Hospital, London
SW17 ORE, and 2Chelsea Hospitalfor Women, London
SW3 6LT, UK.
The LHRH analogue Zoladex (ICI Pharmaceuticals) induces
suppression of gonadotrophin dependent ovarian oestrogen
synthesis and is effective treatment, but only for a limited
period, in premenopausal breast cancer. Peripheral
aromatasation is important in premenopausal women. We
have therefore investigated the endocrine and clinical effects
of the aromatase inhibitor 4-hydroxyandrostenedione
(40HA) (which is an effective treatment for advanced post-
menopausal breast cancer) on its own and in combination
with Zoladex in premenopausal women with advanced breast
cancer.
Six women were treated with the maximum tolerated dose
of 40HA (500mg i.m. weekly) for between 2 and 19 weeks.
No significant reduction in oestradiol (E2) level occurred in
any patient and no patient responded to treatment (NC: 1,
PD: 5). Three (of 4) patients subsequently responded to
Zoladex treatment.
The endocrine effects of the combination of 40HA 500mg
i.m. weekly and Zoladex were studied in 5 patients who were
maintained in remission with Zoladex treatment. Significant
(P<0.01) further suppression of E2 levels occurred 7 days
after 40HA treatment (from a mean of 23.6+4.1 to
6.1 +0.9pmol -1) but gonadotrophins did not change. The
clinical value of combined treatment has been demonstrated
by 1 (of 3) patient who responded, having previously
experienced a remission and subsequently relapsed on treat-
ment with Zoladex alone.
We conclude that 40HA alone is not an effective treat-
ment for premenopausal breast cancer. However, the
combination of 40HA and Zoladex produces more profound
oestrogen suppression and may be a more effective treatment
than Zoladex alone.
The effect of medroxyprogesterone acetate on aromatase and
DNA polymerase ac activities in breast tumours
A. Purohit', M.J. Reed", A. Singh', N.G. Coldham',
M.W. Ghilchik2 & V.H.T. James'
'Department of Chemical Pathology and 2The Breast Clinic,
St Mary's Hospital Medical School, London W2 IPG, UK.
Progestogens such as medroxyprogesterone acetate (MPA)
have been successfully used for the treatment of breast
cancer. As it has been reported that progestogens can
stimulate aromatase activity in endometrial tissue (Tseng et
al., Endocrinology, 1986, 118, 1312), we have examined the
effect of treatment with MPA on tumour aromatase activity
as measured using an in vitro technique. The activity of
DNA polymerase a, which provides an index of cellular
proliferative activity, and plasma levels of cortisol, andro-
stenedione and oestrone were also measured. Blood and
tumour samples were obtained before and after treatment
with MPA (500mgday-1, i.m., for two weeks). Aromatase
activity increased significantly in 4/6 specimens examined
whereas DNA polymerase oc activity decreased in all samples
by 57+25% (mean+s.d.). Plasma cortisol, androstenedione
and oestrone concentrations were significantly reduced after
treatment with MPA. It is concluded that although
treatment with MPA appears to increase aromatase activity
in some tumours this is associated with a decrease in DNA
polymerase a activity. This suggests that the amount of
oestrogen formed in tumours after treatment with MPA is
reduced. The reduction in plasma concentration androstene-
dione that results from the adrenocortical suppression
associated with the use of MPA, suggests that less substrate
will be available for conversion to oestrogen, in spite of the
increase in aromatase activity found in some tumours after
treatment with MPA.
Circulating CA 15-3 in patients with early breast cancer
H.G. Kynaston', R. Fifield2, R.E. Mansell &
D.J.T. Webster'
'Department of Surgery, University Hospital of Wales,
Heath, Cardiff, and 2Protein Laboratory, Cardiff Royal
Infirmary, Newport Road, Cardiff, UK.
CA 15-3 is a recently described breast cancer associated
antigen, defined by two different monoclonal antibodies;
DF3, raised against a membrane enriched fraction of human
breast cancer cell line and 115D8, raised against antigens of
human milk fat globule membranes. It has been claimed that
these breast associated antigenitic determinants CA 15-3 have
been detected at elevated levels in the sera of breast cancer
patients but not elevated in the sera of the majority of
normal individuals (Hayes et al., 1986, J. Clin. Oncol., 4,
1542).
In order to establish its value in the diagnosis of early
breast cancer and its possible use as an adjunct to breast
cancer screening a study was undertaken to evaluate CA 15-3
levels in patients admitted for a diagnostic excision biopsy of
a possible cancer and patients with early breast cancer. Of 47
patients with early breast cancer, mainly stage 1 disease, only
5 patients (10.6%) had a CA 15-3 level greater than the
upper limit of normal of 30 units per ml. Those patients with
micronodal metastases to regional axillary lymph nodes,
examined following mastectomy, had a similar distribution
of serum CA 15-3 levels to those patients without micronodal
involvement. Of 50 patients who underwent excision biopsy
of a breast lump which proved to be benign 4 patients (8%)
had an elevated CA 15-3 level of greater than 30 units per
ml.
Serum CA 15-3 estimations have not been found to be
useful in the investigation of patients with possible earlyBACR/BIR/RSM JOINT WINTER MEETING 825
breast cancer due to its low sensitivity and therefore cannot
be recommended as an adjunct to mammography in breast
cancer screening.
Glycoprotein expression in normal and malignant breast cell
lines
Z. Rayterl & R.A.J. Mclllhinney2
'Department of Surgery, St Peter's Hospital, Guildford
Road, Chertsey, Surrey, UK, and 2MRC Unit of
Anatomical Neuropharmacology, University Department of
Pharmacology, South Parks Road, Oxford, UK.
Glycoprotein expression in normal human breast epithelial
cells has been compared with that in 5 bona fide breast
cancer cell lines MCF-7, T47-D, ZR-75-1, PMC-42 and
Ca2-10, with two SV40-transformed breast cell lines SVE-3
and H-7, and with HBL 100 and MDA-MB-231. Two-
dimensional gel electrophoresis has been employed to
separate detergent-extracted glycoproteins which have been
identified using a '251-Con A overlay. The five bona fide
breast cancer cell lines displayed similar electrophoretic
patterns and intermediate homology (60-71%) with normal
breast cells, although their patterns were somewhat simpler.
All of these cell lines expressed two common novel
glycoproteins, and each cell line expressed other novel
glycoproteins idiosyncratically. SVE-3 and H-7 showed 77%
homology with normal breast and also expressed one of
these glycoproteins. HBL100 and MDA-MB-231 displayed
47 and 51% homology with normal breast cells, implying a
poorly differentiated or non-epithelial cell of origin,
consistent with their lack of differentiated breast cell
function (Engel, L.W. & Young, N.A., 1978, Cancer Res.,
38, 4327). We conclude that although breast cancer cells lose
Con A-acceptor glycoproteins, they also express novel
glycoproteins, two of which are common to all the cell lines,
and some of which are expressed idiosyncratically in other
transformed breast cell lines.
DNA index S-phase fraction and prognosis in breast cancer
S.M. O'Reilly, R.S. Camplejohn, D.M. Barnes, R.R. Millis
& M.A. Richards
ICRF Clinical Oncology Unit, Guy's Hospital, London SE]
9RT, UK.
DNA index and S-phase fraction (SPF) were measured by
flow cytometry on paraffin embedded tissue from 140
primary breast tumours. All patients has stage I or stage II
breast cancer diagnosed between 1973 and 1980, and the
group was selected so that 50% had developed recurrent
disease by the time of this study. The results of DNA
analysis were compared with the size, degree of axillary node
involvement, histological grade and steroid receptor content
of the tumours, as well as with the patients' subsequent
clinical course.
Forty-four of the 140 (31.4%) were diploid. SPF was
evaluable for 134 (95.7%). The median SPF of the whole
population was 7.1% with diploid tumours having a
significantly lower SPF (3.2%) than aneuploid (10.1%,
P<0.001). Both aneuploidy (P =0.002) and high SPF
(P<0.0001) were strongly associated with high
histopathological grade. There was no significant association
between DNA ploidy or SPF and tumour size, nodal status
or steroid receptor content. An SPF below the median was
strongly associated with better relapse free survival
(P=0.008), survival from diagnosis (P=0.004), and survival
after relapse (P=0.001). Ploidy did not correlate significantly
with clinical course.
Multivariate analysis showed that nodal status, tumour
size and Sf'F were independent prognostic factors, but that
the significance of SPF was lost when histological grade was
included in the analysis.
Alteration in the polyamine content of human breast cancer
cells in response to stimulation and inhibition of cell growth
H.M. Wallace & S.J. Cross
Departments of Medicine and Therapeutics, and
Pharmacology, University of Aberdeen, Aberdeen, Scotland,
UK.
The polyamines are naturally occurring cellular polycations
essential for optimal rates of cell growth and differentiation.
Elevated concentrations of these molecules are present in
many types of cancer cells where they are believed to be
involved in the 'up regulation' of cell growth. The aim of
this study was to determine the changes in intracellular
polyamine concentrations in human breast cancer cells under
conditions of increased (treated with 17,B-oestradiol) and
decreased (treated with methylglyoxal bis guanylhydrazone;
MGBG) cell growth. ZR-75-1 cells were grown routinely in
Dulbecco's medium supplemented with 10% (v/v) horse
serum at 37°C in a humidified atmosphere of 95% air/
5% CO2. Cell growth was measured as the change in protein
content (Lowry et al., 1951, J. Biol. Chem., 193, 265) and
polyamine content was measured by hplc (Wallace et al.,
1988, Biochem. J., 253, 223). Growth of ZR-75 cells was
increased by treatment with 17,B-oestradiol. This increase was
accompanied by a similar increase in the total polyamine
content in particular an increase in intracellular spermine
concentration. MGBG, as inhibitor of polyamine
biosynthesis, inhibited growth in a dose-dependent manner.
The decrease in growth rate was paralleled by a decrease in
spermine content. A combination of MGBG and 17,B-
oestradiol resulted in a partial recovery of cell growth and
spermine content. Therefore it may be that spermine is the
polyamine involved in the regulation of growth of these
breast cancer cells.
Characterisation of new hormone-response transplantable rat
mammary carcinomas
S.A. Eccles & H.P. Purvies
Section of Medicine, Institute of Cancer Research, Sutton,
Surrey SM2 5NG, UK.
The preclinical evaluation of new anti-endocrine agents can
be aided by the use of appropriate hormone-sensitive tumour
systems. Models commonly employed include primary
chemically induced rat tumours, and human mammary
tumours grown as xenografts in nude mice. In order to
overcome some of the difficulties associated with such
systems, we set out to develop transplantable hormone-
responsive tumours with reproducible growth and oestrogen
sensitivity in syngeneic rats.
We now describe the characteristics of 2 groups of such
tumours: The HOSP series arose spontaneously in aged
CBH/Cbi rats, OES lines were developed from a tumour
induced by implantation of an oestrogen pellet. Both types
of tumour are hormone-responsive in that their growth is
enhanced by oestrogen supplementation and totally inhibited
in males or ovariectomised females. In addition, tumours
regress or show stasis of growth in response to treatment
with 4-hydroxyandrostenedione, aminoglutethimide and
Tamoxifen. Under certain dosage schedules Tamoxifen was
shown to be 'oestrogenic' and, like oestrone, enhanced both
haematogenous and lymphatic metastasis.
These cell lines are now being used to screen new anti-
endocrine drugs, and to investigate autocrine and paracrine826 BACR/BIR/RSM JOINT WINTER MEETING
influences in the progression of mammary carcinomas
towards hormonal independence and metastasis.
Erythrocyte membrane stearic:oleic acid ratios in breast and
colorectal cancer
J.P. Neoptolemos', B.S. Thomas2 & I.S. Fentiman3
'University Department of Surgery, Dudley Road Hospital,
Birmingham B18 7QH, 2ICRF, Lincoln's Inn Fields, London
WC2A 3PX, and 3ICRF, Clinical Oncology Unit, Guy's
Hospital, London SE 9RT, UK.
A previous report (Wood et al., 1985, Br. Med. J., 291, 163)
had shown increased oleic acid in erythrocytes associated
with solid malignancies and the stearic:oleic acid ratio was
proposed as a sensitive diagnostic test. This could not be
substantiated (Soreide et al., 1987, Br. Med. J., 294, 548) but
there were difficulties in the methodology of both studies.
Samples obtained from two units specialising in breast and
colorectal cancer were analysed 'blind' for the erythrocyte
membrane stearic: oleic acid ratios using appropriate
techniques. Fatty acids were extracted from membranes
following saponification and methylated. Analysis was
performed by gas liquid chromatography using a CPSil 88
fused silica quartz capillary column (50m x 0.32mm) with
flame ionisation detection. A total of 167 subjects were
studied. The mean stearic: oleic acid ratio (±s.d.) in 44
breast cancer patients, 1.24 (0.26) was not significantly
different from 30 healthy controls, 1.10 (0.31) or 18 benign
breast disease cases, 1.20 (0.37). Similar results were
obtained from 34 colorectal cancer cases, 1.08 (0.29) and
their 41 hospital controls, 1.09 (0.32). No relationship was
found between age, sex, grade of tumour differentiation or
stage of cancer and this ratio. The erythrocyte stearic: oleic
acid is of no diagnostic value in patients with breast or
colorectal cancer.
Razoxane adjuvant chemotherapy in Dukes' C colorectal
cancer
K. Hellmann1, J.M. Gilbert2, J.T.C. Irwin3, M. EvansI &
P.G. Cassell2
'The Westminster Hospital, London SW], 2Wexham Park
Hospital, Slough, Berkshire, and 3ICRF Cancer
Chemotherapy Unit, Westminster Hospital, London, UK.
Adjuvant treatment for resectable colorectal cancer has so
far failed to show any effect. Razoxane (Rz) was therefore
used because it had previously been shown to be effective as
a single agent in CRC. One hundred and three Dukes' B
and 89 Dukes' C patients were randomised to receive either
usual clinical care (UCC) or UCC with Rz (p.o. 125 mgb.d.,
5 days per week).
At 5 years, recurrence free interval (RFI) and survival
were not significantly different for Dukes' B patients. For
Dukes' C patients, on the other hand, RFI was significantly
longer in Rz treated patients (by log rank analysis P<0.05).
Differences in survival were just outside statistical
significance. Some patients, however, although randomised
to Rz, did not take any. When analysed according to
whether or not patients received Rz, Dukes' C patients
taking Rz did show a significantly longer survival (by log
rank P<0.05). Toxicity was minimal, but 3 patients on Rz
developed acute leukaemia after 1.5, 3 and 6 years of
continuous Rz treatment. Therefore treatment now ceases at
2 years for Dukes' B and 3 years for Dukes' C. At 2 years
the RFI for the 'as treated' groups in Dukes' B is 76.7% for
Rz treated and 67.3% for controls (P>0.1), and 80.8%
against 74.0% for survival (P>0.1). For Dukes' C patients
at 3 years RFI is 41.8% in patients receiving Rz compared
with 24.7% in the untreated (P<0.025) and 40.1% of Rz
treated patients are alive compared with 25.5% of the
untreated patients (P<0.05).
This was the first time that adjuvant chemotherapy
showed any significant benefit on the Dukes' C group of
colorectal cancer patients. These results warrant further
examination of adjuvant Rz in Dukes' C colorectal cancer.
Potential of Fab/c fragment for cancer therapy
S. Demignot, M.C. Garnett & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
F(ab)2 and Fab fragments have shown no advantage over
whole antibody for tumour therapy mainly because the
improved diffusion is offset by a more rapid clearance from
the body. Arend & Silverblatt (1975, Clin. Exp. Immunol.,
22, 502) showed that the Fc portion seems to control the
catabolism of the antibody. We have therefore investigated
the Fab/c fragment, which is the same size as F(ab)2 but
contains an Fc portion. If Fab/c clears at the same rate as
antibody and maintains a good affinity for the target
antigen, it should concentrate better in the tumour. Fab/c
fragment was obtained by DEAE ion exchange and gel-
permeation chromatography purification of pepsin digested
mouse monoclonal antibody IgG2b 791T/36.
Blood clearance curves of iodinated whole antibody and
Fab/c fragments were similar in shape, but Fab/c fragment
curves were always below the Ab curve. This suggests that
the Fab/c fragment diffused better but was catabolised more
rapidly than antibody. Biodistribution experiments showed
that Fab/c fragments diffuse significantly more rapidly
throughout the body; the carcase in particular. During the
catabolic phase, for the same blood concentration of Ab and
Fab/c fragment there would be 25% more Fab/c fragment
than Ab in the carcase. Expressed as % of injected dose,
there was more Fab/c in the carcase during the distribution
phase (17 hours after injection) and equal amounts when the
equilibrium is reached, confirming the slightly enhanced
catabolic rate of Fab/c fragment compared to whole
antibody.
Tumour associated antigen expression in colorectal cancers
and their metastases
A.J. Jewkes, M.C. Crowson, F. Macdonald & J. Crocker
Surgical Immunology Unit, Department of Surgery, Queen
Elizabeth Hospital, Birmingham B15 2TH, UK.
Heterogeneity of tumour associated antigen expression
(TAA) between colorectal primary tumours and their
metastases have seldom been investigated. Previous histo-
chemical studies have concentrated on primary tumour
antigen expression and few metastatic lesions have been
examined. Histological sections from 20 colorectal primaries
and 74 synchronous lymph node metastases were examined
by indirect immunoperoxide staining. Seven monoclonal
antibodies to TAAs were used: 4 anti-CEA and 3 non-CEA
antibodies (CA19-9, HMFG 1, HMFG2). On two separate
occasions each section of tumour was graded independently,
by two observers, for tumour differentiation, the number of
tumours positively stained by each antibody, the degree each
antigen was expressed by each tumour, and the difference in
cell expression between different antibodies in the same
tumour.
All primary tumours expressed CEA to some extent but
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epitope. None of the non-CEA antigens were universally
expressed by the primary lesions. The degree of expression of
CEA and non-CEA antigens was not related to tumour
differentiation. CEA negative tumours only rarely express
other TAA used in this study. Heterogeneity of TAA
expression was demonstrated between primary tumours and
their metastases and between metastases from the same
tumour with all antibodies studied. Metastases negative for
CEA rarely expressed any of the non-CEA antigens. To
accurately stage and treat colorectal cancer using
radiolabelled MAbs, it is essential that all tumour sites
express the appropriate TAA. This study clearly shows this
is not the case. Investigation of agents to increase TAA
expression might prove useful.
Augmentation of CEA expression in gastrointestinal cancer
A.J. Jewkes, F. Macdonald, B. Russell, C. Jones,
D. Croom & W.H. Allum
Surgical Immunology Unit, Department of Surgery, Queen
Elizabeth Hospital, Birmingham B15 2TH, UK.
Heterogeneity of CEA expression is common to most human
gastrointestinal cancers and has important implications for
the use of monoclonal antibodies in diagnosis or therapy of
these tumours. Agents which could render CEA expression
more homogeneous could result in improved antibody
binding and more efficient diagnostic and therapeutic results.
The level of expression of certain tumour associated antigens
has been reported to be altered by recombinant interferons
and theophylline.
We have investigated the effects of these agents on CEA
expression in 4 colorectal cancer cell lines (LS174T,
Colo 320, HT-29, LoVo), a gastric cancer cell line (MKN45)
and human fibroblasts. All cell lines have been well
characterised and cover a wide range of natural CEA
expression. The drugs were added to cell culture in varying
concentrations and incubated for 24 hours. Utilising flow
cytometry with a specific murine monoclonal anti-CEA
antibody (11-285-14), we found CEA expression was
significantly increased (P<0.001) in certain cell lines with a
interferon (Colo 320, LoVo) and with theophylline (HT-29,
Colo 320, LoVo). Augmentation of CEA expression
appeared dose dependent. Two cell lines were resistant to the
effects of both drugs (LS174T, MKN45). Fibroblasts could
not be induced to express CEA. Response was not related to
tumour cell differentiation or initial level of CEA expression.
Cell surface receptors are necessary for these drugs to alter
antigen expression and heterogeneity of receptor expression
could account for the variable response of the cancer cells
studied. Although both agents can substantially increase
CEA expression in some gastrointestinal cancers, the effect is
not universal and may limit its effectiveness in the diagnosis
and treatment of human cancer with antibodies.
Repeated antitumour antibody therapy in man: use of
cyclosporin A to suppress the host response
J.A. Ledermann, R.H.J. Begent, A.M.B. Kelly, S.R. Wood,
D.B. Smith & K.D. Bagshawe
Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross, and Westminster Medical
School, London W6 8RF, UK.
Therapy of cancer with intravenous antitumour mouse
monoclonal antibodies alone or conjugated to radionuclides
or toxins has produced tumour responses but these are
seldom sustained. Repeated therapy would probably be more
effective but is prevented by the formation of human
antimouse antibody (HAMA) after one or more injections of
antitumour antibody. Cyclosporin A (CsA) has recently been
shown to prevent the antibody response to repeated
injections of mouse monoclonal antibodies in rabbits
(Ledermann et al., Br. J. Cancer, in the press). This study
investigates the effect of CsA on the formation of HAMA in
patients with CEA-producing tumours treated with repeated
doses of a 131-iodine-labelled mouse monoclonal antibody to
CEA. In 3 patients receiving no CsA the mean HAMA level
had risen to 1,998pgml-1 2 weeks after the second injection
of antibody. HAMA production was suppressed in 3 patients
receiving high dose CsA (24mgkg -1 day - I for 6 days
starting 3 days before each antibody injection) and in 3
patients given low dose CsA (5mgkg- 1 day- I continuously
starting 3 days before first antibody injection). HAMA levels
were 3.5pgml-1 and 1.97pgml-1 2 weeks after the second
injection of antibody for high and low dose respectively. Up
to four courses of antibody could be given to patients in
whom HAMA was suppressed. Blood CsA levels were
between 1,000-1,500ngml 1 for the high dose group and
200-400ngml-1 for the low dose. Nausea, vomiting and
anorexia were severe and prolonged with high dose CsA but
were less frequent and less severe with the low dose. WHO
grade 1 renal toxicity was seen in both groups. Low dose
CsA provides satisfactory suppression of HAMA with more
acceptable side effects than a high dose CsA regimen. This
allows the administration of repeated antibody injections and
increases the potential for effective antibody targeted therapy
of cancer.
A preliminary study of the biodistribution of intraperitoneal
791T/36 antibody in ovarian cancer
M.V. Pimm', A.C. Perkins2, C. Gie3, R.A. Marksman',
L.D. Durrant', V.S. Byers4 & R.W. Baldwin'
ICancer Research, 3Obstetrics and Gynaecology, 2Medical
Physics, University of Nottingham, UK, and 4Xoma Corp.,
California, USA.
Monoclonal antibodies are potential vectors for targeting
diagnostic isotopes or therapeutic agents to tumours.
Ovarian cancer is largely confined to the peritoneal cavity
and may be more effectively treated by intraperitoneal (i.p.)
rather than systemic (i.v.) injection. In the present study,
cells from ovarian tumours were shown to react with the
791T/36 antibody. Patients with stage III disease were given
1311 or "'In labelled 791T/36 antibody i.p. Gamma camera
imaging was performed immediately and at 48 hours, the
latter before and after peritoneal lavage. Blood kinetics and
urinary excretion were followed and radiolabel quantified in
resected tumour specimens. The development of anti-mouse
antibodies (AMA) was assessed by an ELISA assay.
Blood levels of both radiolabels rose over the first 20-40
hours reaching 8-14% of the dose in the total circulation
and then declined with T1/2 of 40 hours. Radiolabel was still
attached predominantly to antibody as shown by
precipitation with anti-mouse IgG antiserum. There was little
urinary excretion of "'In (<4% by 4 days) but 1311 was
excreted (T112 =42 hours). Interpretation of the images was
less clear than in previous studies with antibody given i.v.
(Powell et al., 1987, Am. J. Gynecol., 157, 38) but in patients
undergoing laparotomy there was agreement between site of
uptake and surgical findings. Resected tumour specimens
had up to 0.02% of the doseg- but because radiolabel
appeared in the blood it is unclear whether tumour uptake
was from the circulation or local infiltration. All patients
produced AMA.
Further studies are intended to determine the most
appropriate route of administration of antibody or
conjugates for therapy of ovarian cancer.828 BACR/BIR RSM JOINT WINTER MEETING
In viro distribution and fate of protein microsphes in the
rat
N. Willmott'. J.A. Goldberg2. Y. Chen'. C. McArdle2 &
A.T. Florence'
'Department of Pharmacy, Universitl of Strathclyde,
Glasgow and 2Department of Surgery, Royal InfirmarY,
Glasgow-, UK.
Protein microspheres were developed in order to (a) localise
cancer therapeutic agents (cytotoxic drugs, radionuclides) in
desired organs. (b) prolong residence time of these agents at
the site of action. (c) biodegrade to permit multiple dosing.
Our previous studies showed that microspheres (20-40pm
mean diameter) are trapped in target organ capillaries of
animals and patients after injection at the appropriate point
in the vascular system: diversion of microspheres to tumour
deposits in target organs is possible with vasoactive agents
by selectively constricting blood vessels supplying normal
tissue. Once embolised a number of factors influence efficacy
of incorporated therapeutic agents. e.g. residence time of
microspheres at site of action which is determined by raterof
biodegradation. In this study we have examined rate of
biodegradation and subsequent fate of 251I-labelled micro-
spheres prepared from albumin and casein following intra-
hepatic arterial injection (liver as target organ) and i.v.
injection (lung as target organ). Rate of biodegradation is
expressed as T-50 i.e. time take for loss of 5000 of
radioactivity initially localised in target organ. In *itro
studies showed both types of microsphere to be stable in
serum at 37 C. In vivo studies showed that in both liver (T-
50 albumin=3.6 days: T-50 casein=6.8 days) and lung (T-50
albumin =2.0 days: T-50 casein =3.5 days) casein
microspheres biodegraded more slowly that albumin.
The distinctive biodistributive characteristics and control
over rate of biodegradation offered by this novel system may
prove useful in delivery of cytotoxic drugs and radionuclides
in cancer therapy and also help to elucidate the importance
of duration of exposure to these agents.
Childhood malignant liver tumours in the UK 1968-1984: the
importance of complete surgical resection
E.A. Shafford'. J. Pritchard'. G.J. Draper2. C.A. Stiller2 &
J.W. Keeling3
'Hospitals for Sick Children, London, 2CCRG, Oxford and
3John Radcliffe Hospital, Orford, U'K.
To study trends in survival and advances in chemotherapy
and surgery for childhood malignant liver tumours, a survev
was undertaken of 169 cases occuring in the UK from 1968
to 1984. There were 105 hepatoblastoma (Hbl) 33
hepatocellular carcinoma (HCCa) 26 other tumours and 5
whose histology is in doubt. The male female ratio was 1: 1.1
for Hbl and 1: 1.09 for HCCa. Median age at diagnosis was
17 months and 9 years 11 months respectively. Commonest
presenting symptoms for Hbl and HCCa were abdominal
mass distension 67%:50%. anorexia 37%:32%. and
lethargy 29%: 37%. Jaundice occurred in 18% HCCa but
only 6% Hbl. 58% Hbl were anaemic at diagnosis compared
to 33% HCCa. 36 56 (64%) Hbl and 10 24 (42%) HCCa
had platelet counts >500 x 1091-1. Serum AFP was elevated
in 50 56 (89%) Hbl and 9'13 (69%) HCCa but was normal
in 6 Hbl and 4 HCCa. Two Hbl have a family historv of
familial adenomatous polyposis. The majority of patients
(63% Hbl and 76% HCCa) had stage III and IV disease at
diagnosis. Three year survival for 1968-74 is 15% Hbl and
11% HCCa compared to 28% Hbl and 21% HCCa for
1975-84. 45 Hbl and 9 HCCa had complete surgical
resection of primary tumour: 44% of each survive at 3 years.
Only 1 60 Hbl and 0/23 HCCa survive after incomplete
resection. There are no survivors of local relapse but 3
21 Hbl survive after metastatic recurrence. Thus complete
surgical resection is of paramount importance in the survival
of patients with hepatocellular tumours. The trend to
improved survival over the two periods is probably due to
improvements in chemotherapy and surgical techniques.
Supported by the Thomas Kately Fund and the South
Essex Medical Education and Research Trust.
High rate of complete surgical resection (CSR) in advanced
hepatoblastoma (Hbl) after cisplatinum/doxorubicin
('PLADO') chemoteapy
E.A. Shafford'. J. Pritchard', P.N. Plowman'.
V.A. Broadbent', L. Spitz', E.H. Howard'.
A.P. Mowat2 & G. Mieli-Vergani2
'Hospitals for Sick Children, London, and 2Kings College
Hospital, London, LK.
Two-thirds of patients with Hbl present with advanced
disease and the biggest obstacle to cure is conversion of
unresectable to resectable tumour. Since 6 83 13
consecutively diagnosed patients with advanced Hbl have
been treated with cisplatinum (PLA= lOOmgrm-2) and
doxorubicin (DO =50mgm-2 as bolus) = PLADO' 3
weekly. prior to and, or following surgery. The 8 males and 5
females were aged 1-53 months (med 17 months). Serum
AFP at diagnosis ranged from 409-1.700.000pg1-'. Eight
patients had stage IIIA tumours (macroscopic residual
inoperable). 1 stage IIIB (multifocal primary) and 4 stage IV
(lung metastases). One patient had a transient response to
PLADO' but died 4 months from diagnosis, of progressive
tumour. One patient had initial surgery followed by
PLADO'. The other 11 patients showed sustained response
to chemotherapy (CT) alone with a steep fall in serum AFP
values, 2 patients having normal levels (<5upg1-1) prior to
surgery. Lung secondaries cleared in all 4 stage IV patients.
Two patients have not yet come to surgery but the remaining
9 patients all had CSR of primary tumour at a median of
4.5 months (range 2-6 months) from diagnosis. One patient
has since had a local relapse and died, a second patient has
had a metastatic recurrence but is disease free after further
treatment, the rest have completed therapy and survive 7-44
months from diagnosis. DO cardiomyopathy occurred in 2
patients (total doses 400mgm 2 and 350mgm 2). The first
died in cardiac failure; the other survives, on digoxin. 39
months from diagnosis.
We conclude that 'PLADO' with surgery is effective
treatment for advanced Hbl with substantially higher CSR
than in our previous experience. without the use of
alkylating agents and with a median duration of CT of only
5 months. Drug toxicity, especially DO, is of concern, but all
survivors have excellent quality of life. Two teenage patients
with multicentric hepatocellular carcinoma (HOC) had good
clinical AFP responses to 'PLADO': the combination
therefore seems worthy of a trial in adults with HOC.
Supported by the Thomas Kately Fund and the ICRF.
Importance of schedule for giving methotrexate and
cisplaiuum in combination to treat patients with transitional
cell carcinoma
R.T.D. Oliver & S.J. Popert
Department of Medical Oncology, The London Hospital,
London, U'K.
As both metrotrexate and cisplatinum are nephrotic drugs
their use in combination has always been associated with theBACR/BIR/RSM JOINT WINTER MEETING 829
risk of increased nephrotoxicity. As a consequence most
regimens using the two drugs give methotrexate 24h prior to
cisplatinum. Following reports from Kaye showing that
giving platinum at the same time as methotrexate did not
alter methotrexate clearance, a phase 2 study was initiated
giving both drugs synchronously. Fifty-one patients receiving
this schedule, (group 1) and 53 patients receiving
methotrexate 24h prior to cisplatinum (group 2) have been
studied. We found that 28 of 51 patients in the first group
developed renal impairment sufficient to necessitate a
reduction in dosage of cisplatinum or termination of
treatment. This compared with 15 of 53 patients in the
second group. (P=0.01). It is concluded that it is not wise to
give methotrexate and cisplatinum without a 24-h gap in
between.
Comparison of cyclophosphamide, adriamycin, vincristine
(CAV) and ifosfamide, etoposide (IE) in small cell lung
carcinoma (SCLC): a randomised study
S.W. Watkin, J.A. Green & H.M. Warenius
CRC Department of Radiation Oncology, Clatterbridge
Hospital, Wirral L63 4JY, UK.
High response rates have been reported for several new
drugs including etoposide, ifosfamide and cisplatin in the
treatment of SCLC in various recent non-randomised
studies. In the present study, 90 patients with SCLC have
been randomised to receive either CAV (Greco, 1978,
B.M.J., ii, 10) or IE (I 5gm-2 i.v. day 1 with Mesna;
E 100 mgm-2 i.v. dayl-3) every 21 days, given to complete
remission+2 cycles. Patients in CR are randomised to receive
thoracic irradiation (45 Gy in 15 fractions) or no further
treatment. Fifty-nine patients have completed chemotherapy:
35 male, 24 female; median age 62 years, range 41-71 years.
Median ECOG Performance status is 1 on both arms of the
study and the mean number of cycles of chemotherapy is 4
on each arm. Reponse rates for regime A are CR 12 (42%),
PR 7 (24%), SD 7 (24%), PD 3 (10%), NE 2 and regime B,
CR 8 (33%), PR 7 (29%), SD 7 (29%), PD 2 (8%) and
NE 4. Median survival is 7 months for regime A and 11
months for regime B (P=0.19). Survival is superior for
22 LD patients (LD vs. ED P<0.05). There have been 5
deaths in which toxicity may have been contributory (4 with
regime A, 1 with regime B). Nausea and vomiting is grade 2
for regime A and grade 3 for regime B. The benefit of
thoracic irradiation in CR is being assessed in a second
randomisation. So far there are important differences in the
toxicity profiles of the two regimes but no significant
differences in response or survival. Stage is an important
prognostic factor.
Accurate dosimetry for targeted radionuclide therapy
S.E. Dewhurst, S.J. Riggs, A.J. Green. R.H.T. Begent &
K.D. Bagshawe
Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross and Westminster Medical
School, London W6 8RF, UK.
The development of targeted therapy of cancer requires that
the distribution of the therapeutic agent in tumour and
normal tissues is reliably estimated. Gamma camera imaging
has the potential to achieve this. However, present methods
cannot accurately quantify radioactivity in sites with
significant activity in tissues overlying those being studied. A
method has been developed using single photon emission
tomography (SPET) with correction for Compton scatter
(Jaszczak et al., 1984, J. Nucl. Med., 25, 893) to permit
accurate measurement of activity in tumour and normal
tissues of patients receiving 131Iodine labelled antibody. An
IGE Gemini gamma camera with 400keV collimator was
used to acquire tomographic images of a phantom
containing sources with levels of radioactivity similar to
those found in human tumours in a background of lower
levels of activity. The background was increased in
increments of 0.2 from 0 to 1.2,iCiml-1. Scatter corrected
reconstructions gave accurate estimates of activity in the
source regardless of background activity. Without correction
there was an apparent rise in activity of 60% in the source.
With planar reconstruction apparent activity in the source
rose by up to 560%. The validity of the method was
confirmed in patients by comparing activity in the cardiac
ventricles measured by SPET with scatter correction with
that in a simultaneous blood sample. A coefficient of
correlation of 0.955 was achieved with 25 data points. SPET
with scatter correction was compared with planar imaging in
measuring activity in the liver and spleen of patients
receiving 75mCi 131I-antibody to CEA intravenously. Planar
imaging gave significantly higher values than SPET for the
spleen (t=5.4, P<0.001 by the paired t test) but no
significant difference for the liver. This shows the
overestimation of activity by planar imaging structures like
spleen or tumour which is overlaid by other tissues. SPET
with scatter correction forms a basis for an improved
technique of quantifying the targeting efficiency.
The distribution and dosimetry of radiolabelled antibody in
radioimmunotherapy
R.H.J. Begent, J.A. Ledermann, A.J. Green, S.J. Riggs,
F. Searle, T. Adam, P.A. Keep & K.D. Bagshawe
Cancer Research Campaign, Labs, Charing Cross Hospital,
London W6 8RF, UK.
Antibody targeted therapy of cancer requires that a
favourable distribution of antibody is sustained in tumour
relative to normal tissues. The necessary data showing the
time course of antibody distribution in man are lacking. The
distribution of 40-150mCi of intravenously administered
131-iodine labelled antibody to carcinoembryonic antigen
has been studied in 16 patients with colorectal cancer. The
distribution of antibody was measured by gamma camera
imaging using single photon emission tomography with
scatter correction (Riggs et al., 1988, Int. J. Cancer, suppl. 2,
95, 1988) and planar imaging as appropriate. Maximum
concentrations of radioactivity were found in tumour 8
hours after administration. Activity in tumour varied up to
9-fold in different patients. Higher levels were found on
average in tumour than any other tissue. Liver, lung and
blood were the other tissues in which antibody was
concentrated relative to the rest of body. Antibody cleared
from all these tissues over 1 week. Second antibody directed
against the antitumour (first) antibody was given 24 hours
after first antibody in order to accelerate clearance from the
blood. This increased the tumour to blood ratio but had
little effect on other tissues. Cumulative radiation dose to
tumour and normal tissue was estimated and showed that in
patients with the most efficient localisation the tumour to
body ratio was 20: 1 and tumour to blood ratio 5: 1. This
may be sufficient for effective therapy of cancer in patients
selected for efficient antibody localisation.830 BACR/BIR/RSM JOINT WINTER MEETING
Breast cancer immunoscintigraphy with 1231 and 125I-labelled
monoclonal antibody (Mab) SM3
C. Twelves', S. Clarke', A. Girling', C. Lazarus',
S. Allen', J. Taylor2, J. Burchell', S. Mather3,
M.A. Richards' & R.D. Rubens'
'ICRF Clin. Oncol. Unit, and Div. Radiobiological Sciences,
Guy's Hospital, London SE]; 2ICRF Labs, London WC2,
and 3St Bartholomew's Hospital, London EC], UK.
A mouse antibody, SM3, has been evaluated in breast cancer
patients undergoing mastectomy with axillary clearance.
SM3 was labelled with 1231 to assess early (24h) or 1251 to
assess late (72h) uptake. Labelled SM3 was injected either
subcutaneously (s.c.) into the finger web spaces of both
hands, or intravenously (i.v.). With 1231-SM3, patients were
injected 24h before surgery, imaged preoperatively, and the
resected specimen imaged postoperatively. Radioactivity was
counted in the surgical specimen and it was examined
histologically. With '251-SM3, the patients underwent
mastectomy 72h after injection, the surgical specimen was
examined histologically and radioactivity counted. Images
cannot be obtained with 1251.
Fourteen patients have been studied. Imaging with 1231_
SM3 showed symmetrical axillary uptake and uptake in
resected lymph nodes. The images did not correspond to
histologically proven metastases, and the primary tumour
was not visualised. Radioactivity in the surgical specimens is
shown in the table as mean % injected 1231 or 1251 g- I tissue.
1231-SM3 123I-SM3 125I-SM3 1251-SM3
(s.c.) (i.v.) (i.v.) (i.v.)
n=4(24h) n=4(24h) n=2(72h) n=4(72h)
Normal nodes 0.007 - 0.0066
Metastatic nodes 0.005 - 0.036
Normal tissue - 0.005 - 0.0007
Primary tumour - 0.0037 - 0.0024
This is a valuable model for evaluating immunoscinti-
graphy in breast cancer. We have not shown tumour-specific
uptake of SM3 in lymph nodes or primary tumour 24h after
injection. However, preliminary data with 1251-SM3 suggests
specific uptake may be detectable at 72h.
1311 mIBG absorbed dose estimates in neuroblastoma:
calculations based on tumour-biopsy data
J.W. Babich, J.S.E. Moyes & S.L. Fielding
Royal Marsden Hospital and Institute of Cancer Research,
Sutton, Surrey, UK.
In an effort to understand more fully the potential role of
1311 mIBG in the treatment of neuroblastoma, a study was
undertaken to determine the quantitative tumour uptake of
this radiopharmaceutical. Six children with neuroblastoma, 1
with ganglioneuroma and I with ganglioneuroblastoma were
injected i.v. with 1251 mIBG, 24-48 h prior to surgical
removal of the tumour. Percent injected dose per gram of
tumour was calculated and histopathology performed on all
surgical specimens. The mean range of uptake in these
tumour specimens were 0.0022-0.2% injected doseg-1. A
wide range of intra- and inter-tumour variation of mIBG
uptake was demonstrated which was related to tumour
pathology.
Absorbed dose estimates have been calculated for this
range of tumour uptake for various activity-residence times
and tumour masses, similar in magnitude to patient data.
Based on these data, tumour dose estimates were in the
range 0.11-10.4GyGBq- 1 (effective half-life, T, of 24h), to
0.45-41.8GyGBq - (T=96h). From these calculations, it
seems likely that certain patients will receive sterilising
radiation doses to tumours and therefore a suitable means of
selecting patients for therapy is required. In addition,
microdosimetry must be evaluated in order to determine the
absorbed dose to small tumour masses.
Localised 31p magnetic resonance (MR) spectroscopy in
patients with cerebral gliomas
C.J. Twelves', D. Porter', M. Lowry', M.A. Smith',
P. Heasley', P. Garlick', A. Moore2, A. Bell2,
M. Maisey', R.D. Rubens' & M.A. Richards'
'ICRF Clinical Oncology Unit, and Div. Radiological
Sciences, Guy's Hospital and 2Atkinson Morley's Hospital,
London, UK.
We have obtained localised 31P brain spectra from 15
patients with primary brain tumours >3 cm diameter and
from 17 healthy volunteers with a 1.5 Tesla Philips imaging
and spectroscopy system. Spectra were acquired using image
selective in vivo spectroscopy (ISIS) from regions identified
on MR images. The volume of brain studied was 125cc for
each volunteer. In 8 untreated glioma patients the tumour
was studied, and in 6 glioma patients brain tissue outside the
tumour was studied. The following peaks were identified:
phosphomonoesters (PME), inorganic phosphate (Pi),
phosphodiesters (PDE), phosphocreatine (PCr), y-, x- and ,B-
ATP. Tissue pH was calculated from Pi-PCr chemical shift,
Peak areas were expressed as % of total 31P signal, PCr/Pi,
PCr/,B-ATP and PDE/PME peak area ratios were calculated.
31P spectra from brain tissue outside the tumour in glioma
patients did not differ significantly from spectra from
volunteers. All spectra collected from gliomas were
abnormal. Mean values which differed significantly
(Wilcoxon's rank sum test) from those in healthy volunteers
are shown below.
pH Pi PDE PCr/Pi
Volunteers (n=7) 7.00 6.75 30.8 2.46
Glioma (n=8) 7.13 9.51 26.2 1.78
P value <0.01 <0.05 <0.01 <0.01
These results show differences in bioenergetics (Pi and
PCr/Pi), pH and membrane metabolism (PDE) between
gliomas and normal brain. Similar abnormalities were
observed in a patient with relapsed medulloblastoma. These
resolved within 2 weeks of starting radiotherapy, before
tumour size changed.
In vivo 31P nuclear resonance spectroscopy of human breast
carcinoma: the importance of localisation
J. Glaholm, J.C. Sharp, D.J. Collins, V.R. McReady,
A. Hind & M.O. Leach
The Royal Marsden Hospital and Institute of Cancer
Research, Sutton, Surrey, UK, and Siemens Ltd, Sunbury on
Thames, UK.
In vivo 31P nuclear magnetic resonance spectroscopy
provides for non-invasive assessment of the response of
tumour metabolism to therapeutic intervention. Early
prediction of treatment response and disease relapse are of
considerable clinical importance.
The anatomical proximity of the breast to underlying
skeletal muscle necessitates an accurate method of volume
localisation in order to prevent spectral contamination byBACR BIR RSM JOINT WINTER MEETING 831
the strong signal from muscle. We have demonstrated the
efficacy of a modified ISIS localisation sequence and the
inadequacy of surface coil localisation'.
Six patients with locally advanced breast carcinoma have
been assessed during treatment. Four were treated with
combination chemotherapy. I with tamoxifen and I with
external beam irradiation. Two patients responding to
chemotherapy demonstrated spectral changes. in one case
these preceded the clinical response. The tamoxifen treated
patient similarly demonstrated spectral changes. however
these were not shown to precede clinically measurable
changes. The patient treated with external beam irradiation
showed general signal reduction which parallelled tumour
volume reduction. however surprisingly there was no
qualitative spectral change.
Cellular recovery in two lines of the L5178Y murine
lymphoma vwiich differ in their sensitivity to ionisiWn
radiation
T.J. McMillan. J.J. Eadv. J.H. Peacock & G.G. Steel
Radiotherapy Research U-nit. Institute of Cancer Research.
Sutton. Surrey. UK.
Two lines of the murine lymphoma. L5178Y. have been
investigated to assess the role of cellular recoverv in the
determination of their widelv different sensitivities to iorusing
radiation. Two commonly used assays of recovery capacity
have been used. The extent of dose-rate sparing is measured
by comparing the survival of the cells after acute and low
dose rate irradiation and split dose experiments measure the
extent of recoverv when two halves of an acute dose are
separated in time.
LY-R seems to have the greater dose-rate effect when the
dose reduction factor at a survival of 0.01 is used (1.65 and
1.37 for LY-R and LY-S respectively), suggesting that its
recovery capacity is greater.
Split dose experiments do not. however, confirm this.
Classically split dose measurements have been made at a
single dose level which is chosen to give a selected level of
survival (often 0.01) but we have shown that this is
inadequate because recovery ratio (RR) increases with dose.
The linear quadratic equation determines that this increase
in RR with dose is a function of the constant f so that f
gives a better indication of recovery capacity. Making this
comparison between LY-R and LY-S we come to the
conclusion that the most sensitive line has in fact the greater
recovery capacity.
It is apparent, then, that the assessment of recovery
capacity is not straightforward and careful analysis is
required before connections are made between recovery and
cellular sensitivity.
Split-dose recovery reassessed
J.H. Peacock. T.J. McMillan & G.G. Steel
Radiotherapy Research lnit, Institute of Cancer Research.
Sutton, SurreY, UK.
In a recent study of the effect of dose on split-dose recovery
in four human tumour cell lines we suggested that an
increased capacity for cellular recovery did not necessarily
correlate with increased cellular radiosensitivity. We have
now extended this to a total of 16 normal and tumour cell
lines, including several highly radiosensitive human A-T
lines. In addition we have reanalysed previously published
data where the effect of dose has been studied.
Analysis of the results for these lines indicate that: (i) All
lines demonstrate increasing split-dose recovery with
increasing dose. This agrees well with the relationship
predicted by the linear-quadratic equation (equation 1). and
enables us to use the fi value as a measure of recovery:
In (Recovery Ratio)=2(3d2 (1)
where d is dose per fraction and # is from the L-Q equation.
(ii) At any given dose split-dose recovery was greatest in the
most radiosensitive cells. Analysis using equation (1) yields
values for # that increase with increasing radiosensitivity.
The results presented here reinforce our earlier conclusion
that the concept of radiosensitive cells being recovery
deficient is wrong. The importance of this conclusion lies in
the possible relationship between recovery and repair. It is
generally assumed that capacity for cellular recovery reflects
the ability to repair radiation-induced sub-cellular damage. If
this assumption is true then our results suggest that
increasing cellular radiosensitivity does not result from a
decreased ability for repair.
The effects of three bioreductive drugs, mitomycin C, RSU-
1069 and SR4233 on cell lines selected for their sensitivity
to DNA-damaging agents
A. Keohane. J. Godden. I.J. Stratford & G.E. Adams
MRC Radiobiologv U'nit, Chilton, Didcot, Oxon OXIJ
ORD, L'K.
We have investigated the cross-sensitivity of a number of cell
lines to mitomycin C. RSU-1069 and SR4233 under both
aerobic and hypoxic conditions. The cell lines used were
selected for their sensitivity to DNA-damaging agents and
fall into two groups. The first. MMC cells (Robson et al..
1985. Cancer Res., 45, 5304) were derived from CHO-KI
cells and show a range of sensitivities to mitomycin C in air
(D3. values (pgml-) after 3h aerobic incubation are: K1.
0.65: MMC-2, 0.25; MMC-3. 0.17; MMC-R. 8.0). The
second group of cells cloned from V79 fibroblasts (Jones et
al.. 1987. Mutation Res., 183, 279) exhibit sensitivity to
ionising radiation (D37 values (Gy) of these cells are: V79.
4.2; irs1. 1.34; irs2. 1.41; irs3. 2.06). No difference in the
aerobic or hypoxic toxicity of mitomycin C was observed for
the CHO-K1, MMC-2 or MMC-3 cells. However. the
MMC-resistant cell line (MMC-R) was 10 times more
sensitive under hypoxic (D3, 0.8pgml-1) than aerobic
conditions. This suggests that MMC-R cells lack or have a
lower expression of the 02-insensitive reductase system
compared to the other MMC cells. In contrast, all CHO cell
lines showed greater sensitivity to RSU-1069 and SR-4233
under nitrogen compared to air, with differential toxicities
between 3 and 30. There was little or no cross-sensitivity
when compared to the responses to MMC in either air or
N,. Treatment of V79 and irs cells with RSU-1069 and SR-
4233 also resulted in selective toxicity towards hypoxic cells.
Differential toxicities between 50 and 100 were observed in
wild type V79s. For both drugs the hypoxic toxicities were
similar in both the parent and irs cells, but in air the mutant
cells were up to 10 times more sensitive. (Supported by NCI
grant no. ROlCA44 126-01.)
Bioreductive drugs and the selective induction of tumour
hypoxia
J.C.M. Bremner. I.J. Stratford & G.E. Adams
MRC Radiobiologv Unit, Chilton, Oxon OXII ORD, LK.
The hypoxic fraction present in most experimental tumours
provides the possibility of selective cell killing by
bioreductive agents. Increasing tumour hypoxia should832 BACR'BIR RSM JOINT WINTER MEETING
further enhance the efficacy of these agents. Methods of
selectively increasing tumour hypoxia to close to 100%
include clamping or by use of the drugs: hydralazine
(5mgkg - '). or flavone acetic acid. FAA. (200mgkg - 1). We
have measured their effectiveness in potentiating the
bioreductive toxicity of: RSU 1069 (80mgkg ').
misonidazole (800mgkg 1) mitomycin C (5mgkg ') and
SR4233 (50mgkg-1) in KHT and RIF-I tumours grown
subcutaneously in C3H mice. Response to treatment was
measured as the time for tumours to reach 4x initial
treatment volume. For untreated controls this was 3.58 +0.26
and 5.19+0.29 days respectively.
Clamping alone for 90min gave little or no response. but
when RSU 1069 is administered 15min prior to clamping.
large growth delays result in KHT and RIF-I tumours
(17.35+0.49 and 27.52+2.08 days respectively). RIF-1
tumours clamped for 120min with RSU 1069 gave 30%
tumour control with no recurrence at 150 days. Less effect
w-as seen with misonidazole. mitomvcin C and SR4233 in
the KHT tumour (3.63 +0.33. 7.90+ 1.23 and 7.90+0.49 days
respectively). Hydralazine showed some growth delay with
RSU 1069 in the RIF-1 (9.28+0.36) but no effect in the
KHT tumour. FAA alone gives growth delay in the KHT
and RIF-l tumours (9.53 + 1.86 and 8.37+ 1.59 days). but the
addition of 1069 provides little or no increase in this effect.
These results indicate that induction of tumour hypoxia
together with a bioreductive drug can be an effective
approach to therapy. However, the results also imply that
the depth and duration of tumour hypoxia will contribute to
the effectiveness of the bioreductive drug under examination.
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